Glossary 551

**humidity deficit** The difference between what is provided by the humidifier and the amount of humidity required by the patient. **hyperinflation** See *overinflation*.

hyperosmolar A substance or condition with increased osmolarity. hyperthyroidism A condition that results from increased activity of the thyroid gland. An increase in metabolic activity that is characterized by nervousness, tremors, hunger, weight loss, fatigue, palpitations, and related symptoms occurs.

hyperventilation Ventilation in excess of a level required to meet metabolic demands (e.g., PaCO<sub>2</sub> < 30 mm Hg).

hypoventilation A respiratory condition resulting in elevated blood carbon dioxide and generalized reduction in respiratory function. hypoxemia Lower than normal oxygen pressure in the arterial blood. hypoxia Lower than normal oxygen pressure in the alveolus or at the tissue level resulting in an inadequate amount of oxygen available to the body cells to meet their metabolic needs. hysteresis Can be thought of as a lagging of one of two associated phenomena; that is, two associated phenomena fail to coincide or occur simultaneously. An example of hysteresis is the difference between the inspiratory and expiratory curves in a pressure—volume

loop for the lungs.

iatrogenic Caused by a medical procedure or treatment. ileus An obstruction of the intestinal tract associated with immobility of the bowel or a mechanical blockage of the bowel. incisura A small negative deflection on the pressure—time tracing present in the aortic and pulmonary artery pressure tracings; caused by the transient reversal of blood flow toward the heart during the last part of systole that pushes against the respective semilunar valve. independent lung ventilation A form of mechanical ventilation. indirect calorimetry Estimate of the caloric expenditure of the body by measurement of exhaled gas volumes and fractional concentrations of oxygen and carbon dioxide rather than direct heat production from the body.

**inflammatory mediators** Chemical substances produced by the body that are involved in the inflammatory response.

**inflection point** Occurs during deflation (also sometimes called the *deflection point*) and represents collapse of a significant number of lung units after full inflation (recruitment) of the lungs.

**inspiratory pause** Mechanical ventilator setting that involves a short prolongation of the inspiratory phase of a breath. Inspiratory pause or inflation hold maneuvers are used to measure plateau pressure. **inspiratory positive airway pressure** (**IPAP**) The application of positive pressure to the airway during inspiration. Compare *expiratory positive airway pressure*.

inspissated secretions Airway secretions that are thickened or hardened through the loss or evaporation of the liquid portion. intermittent abdominal pressure ventilator (IAPV) A motorized inflatable bladder that fits over the abdomen and assists spontaneous breathing. The motor inflates the bladder, which in turn pushes the diaphragm upward to facilitate exhalation. When the bladder deflates, the diaphragm returns to its resting position allowing for passive inhalation. See *pneumobelt*.

intermittent positive pressure breathing (IPPB) The application of positive pressure breaths to the upper airway on a periodic basis; used to provide short-term or intermittent mechanical ventilation for the purpose of augmenting lung expansion, delivering aerosol medication, or assisting ventilation.

**intermittent positive pressure ventilation** (IPPV) A general term for mechanical ventilation provided by positive pressure. The acronym *IPPV* can also be used to mean *invasive positive pressure ventilation* in which the patient has an endotracheal or tracheostomy tube in place to connect to the ventilator.

**internal pneumatic circuit** A series of gas-conducting tubes on the inside of a ventilator that direct gas flow within the ventilator to the outside of the ventilator for delivery to the patient.

internal respiration Movement of oxygen and carbon dioxide between the cells and blood.

international normalized ratio (PT/INR) Calculation made to standardize prothrombin time. INR depends on the ratio of the patient's prothrombin time and the normal mean prothrombin time. Prothrombin time shows how fast the blood clots in patients receiving oral anticoagulant medication.

intrinsic PEEP (PEEP<sub>I</sub>) See auto-PEEP.

**iron lung** A negative pressure ventilator. Also called a *tank* ventilator, artificial lung, or Drinker respirator.

ischemia A reduction in the flow or supply of oxygenated blood to a body organ or area; may be accompanied by severe pain and organ dysfunction (e.g., cardiac ischemia when an adequate oxygenated blood flow to the heart is lacking).

ischemic Condition characterized by a deficiency of blood supply to an organ.

isothermic saturation boundary The point in the airway where inspired air is warmed and humidified to 100% relative humidity at 37°C and contains 44 mg/L of water (absolute humidity). This point is approximately at the level of the fourth to fifth generation of subsegmental bronchi and varies with rate of gas flow, minute ventilation, and ambient air conditions.

#### K

ketoacidosis Acidosis accompanied by an increase in ketones; occurs primarily as a complication of diabetes mellitus. kinetic therapy The use of automated rotating beds to reduce the incidence of ventilator-associated pneumonia (VAP), particularly in surgical patients or patients with neurologic problems.

#### L

late-onset pneumonia Pneumonia that develops later than 72 hours after exposure to a hospital or clinic setting.

**limit variable** The phase variable whose size is set at some predetermined maximum that cannot be exceeded during inspiration.

lower inflection point A point of significant change in the slope of a static pressure—volume curve at the beginning of lung inflation; indicates the pressure at which large numbers of alveoli are beginning to be recruited; sometimes called  $P_{\rm flex}$ .

### M

mandatory breaths Breaths for which the ventilator determines the start time (time triggered based on the set rate) or the volume (volume targeted) or pressure (pressure targeted) or both the start time *and* the tidal volume or pressure delivered.

mandatory minute ventilation (MMV) A closed-loop system in which the ventilator monitors set parameters and makes adjustments based on those parameters and the patient's spontaneous breathing efforts. The operator sets a minute ventilation ( $\dot{V}_{\rm E}$ ) lower than the patient's spontaneous  $\dot{V}_{\rm E}$ . If monitored  $\dot{V}_{\rm E}$  falls below the minimum set  $\dot{V}_{\rm E}$ , the ventilator increases support to the patient, and vice versa. Also called minimum  $\dot{V}_{\rm E}$ .

mask pressure Term often used to describe the airway opening pressure.

mechanical dead space The amount of rebreathed volume in a ventilator circuit.

meconium aspiration syndrome The inhalation of meconium by the fetus or newborn, resulting in blockage of the airways, failure of the lungs to expand, potential pneumonia, and possible respiratory failure. metabolic monitor Device used to measure concentrations of inspired and expired gases (i.e., oxygen and carbon dioxide), as well as sensors for measuring the volume and/or flow of respired gases. microprocessors Integrated electronic circuits that contain the central processing unit functions of a computer.

minute ventilation The volume of gas per minute inhaled or exhaled from a person's lungs. The calculation of minute ventilation is the product of rate and tidal volume.

miosis The constriction of the pupil of the eye to 2 mm or less. mode Term used to describe various mechanical ventilator strategies employed to deliver a breath. Ventilator modes are typically characterized by how an inhalation is initiated and ends and how exhalation begins.

mouth pressure  $(P_M)$  Pressure at the upper airway (mouth); also called airway opening pressure  $(P_{awo})$ , airway pressure  $(P_{aw})$ , upper airway pressure, mask pressure, and proximal airway pressure. multidrug-resistant (MDR) microorganism A bacteria that resists distinct drugs or chemicals of a wide variety of structure and function targeted at eradicating the organism.

multiple organ failure Modified organ function in an acutely ill patient requiring medical treatment to achieve homeostasis. multisystem organ failure (multiple organ dysfunction syndrome [MODS]) Severe pathological failure occurring all at once of many organ systems, such as the lungs, gastrointestinal tract, liver, and heart; may accompany acute lung injury or acute respiratory distress syndrome.

#### N

**negative end-expiratory pressure** (NEEP) Negative pressure applied to the airway at the end of exhalation during mechanical ventilation. **neonate** A newborn younger than 4 weeks of age.

neurally adjusted ventilator assist (NAVA) A mode of mechanical ventilation that provides respiratory assistance for the patient in comparison to and in synchrony with the patient's respiratory efforts.

**nocturnal hypoventilation** An elevated P<sub>a</sub>CO<sub>2</sub> and accompanying fall in oxygen saturation that occurs in response to a progressive fall in minute ventilation occurring during sleep, most often in the rapid eye movement (REM) stage.

**nondepolarizing agents** Agents that causes skeletal muscle paralysis by causing competitive inhibition of acetylcholine at the muscle receptor site.

**noninvasive positive pressure ventilation (NIV)** Delivery of positive pressure mechanical ventilation to the lungs without the use of an artificial airway.

**nosocomial infections** Infections in hospitals and other health care facilities.

#### 0

obstructive sleep apnea (OSA) A condition characterized by episodes of breathing cessation during sleep. Relaxation of the muscles of the upper part of the throat during sleep causes the upper airway to close, blocking the upper airway (oropharynx) and preventing air from entering the lungs. This results in failure of air movement through the obstructed passage while breathing efforts persist. At least five episodes of apnea (lack of air movement) lasting 10 or more seconds are characteristic of OSA.

oliguria A diminished output of urine relative to fluid intake.

open-loop system A control scheme in which a variable is set and
the operating system makes no comparisons between output and
input signals and no changes to the designated variable; an
"unintelligent" system; the opposite of a closed-loop system.

operational verification procedure (OVP) A checklist used to verify
that the ventilator systems are fully functional and safe before use
with a patient; sometimes a part of the respiratory therapy
department's policy and procedure manual. The self-test performed
by the ventilator may be part of the OVP.

**overdistention** See *overinflation* and *hyperinflation*. **overinflation** When excessive pressure or volume delivery during mechanical ventilation causes too much stretching of lung parenchyma; overdistention or hyperinflation.

#### P

paradoxical breathing Abnormal breathing pattern characterized by movement of the thorax outward during expiration and collapsing inward during a spontaneous breath.

paralytic agents Drugs used to facilitate invasive procedures (e.g., surgery, endotracheal intubation) and to prevent movement and ensure the stability of artificial airways. Paralysis may also be used to decrease mean airway pressure (Paw) during uncoordinated or uncontrolled mechanical ventilation.

partial ventilatory support (PVS) Any amount of mechanical ventilation with ventilator rates that are less than those used with continuous mandatory ventilation (CMV), in which the patient is participating in the work of breathing to help maintain effective alveolar ventilation.

patent ductus arteriosus (PDA) An abnormal opening between the pulmonary artery and the aorta resulting when the ductus arteriosus does not close at birth.

patient circuit A series of gas-conducting tubes that conduct gas from the ventilator output connector to the patient and from the patient to the ventilator exhalation valve; also called the *ventilator circuit* 

patient triggering When inspiration begins because of the ventilator sensing a change in pressure, flow, or volume as a result of a patient effort.

patient—ventilator asynchrony A situation in which the patient breathing pattern and ventilator breathing pattern are not harmonious.

patient—ventilator system check See ventilator flow sheet. peak airway pressure The highest pressure achieved during inspiration on positive pressure ventilation; also called *peak pressure* and *peak inspiratory pressure*.

peak inspiratory pressure See peak airway pressure.

peak pressure See peak airway pressure.

pediatric An infant, child, and adolescent from birth to 21 years of age.

perivascular Pertaining to an area around a blood vessel. permissive hypercapnia Higher than normal  $P_aCO_2$  values resulting from ventilator strategies used to protect the lung from injury associated with the ventilator.

**phase variable** A signal that is measured and used by the ventilator to begin some part (phase) of the breathing cycle.

physiological shunt The total shunt fraction.

plateau pressure A pressure measurement taken during positive pressure ventilation after a breath has been delivered to the patient and before exhalation has begun. A condition of no flow exists, reflecting the pressure in the lungs and patient circuit.

pneumobelt A belt containing a bladder that inflates during

**pneumobelt** A belt containing a bladder that inflates during exhalation to move the diaphragm upward (cephalad) to assist exhalation. Inhalation is passive.

**polymicrobial infection** Infection by multiple pathogenic microorganisms.

polyneuritis Inflammation of many nerves at once or disseminated neuritis.

positive end-expiratory pressure (PEEP) Pressure above atmospheric, applied to the airway during exhalation, that increases the functional residual capacity.

**preload** The filling pressure of the ventricle at the end of ventricular diastole.

pressure augmentation Dual-control mode that provides pressurelimited ventilation with volume delivery targeted for each breath. pressure control A mode of ventilation that is normally patient or time triggered, pressure targeted, and time cycled.

Glossary 553

**pressure cycling** Inspiration ends when the ventilator measures a set pressure during inspiration.

pressure gradient A pressure difference between two points, one pressure being higher than the other.

**pressure limiting** A set maximum pressure that cannot be exceeded. **pressure support** A mode of ventilation that is normally patient triggered, pressure targeted, and flow cycled.

**pressure-targeted ventilators** Ventilators that provide multiple modes for presetting the maximum inflation pressure rather than a fixed tidal volume.

**pressure triggering** When a change in pressure starts gas flow from the ventilator to deliver inspiration.

**problem** An unwelcome or harmful matter requiring immediate attention that must be dealt with and overcome.

**prone positioning** Placing the body with the chest (ventral side) down and back (dorsal side) up.

**prophylactic therapy** Therapy aimed at defending against or preventing disease.

protected specimen brush (PBS) An invasive microbiologic procedure to culture lower respiratory secretions often necessary to ensure effective treatment of patients with ventilator-associated pneumonia (VAP).

proximal airway pressure Term used to indicate an estimate of the alveolar distending pressure.

pruritus Itching leading to the desire to scratch.

**pulmonary angiogram** A radiological image of the pulmonary vasculature bed obtained by injecting an opaque contrast medium into the pulmonary circulation.

**pulmonary artery catheter** (PAC) A long, thin flow-directed tube with a balloon tip on the end (also known as *Swan-Ganz*) that allows it to flow into the right chamber of the heart.

pulmonary vascular resistance The afterload the right ventricle must overcome to eject blood into the pulmonary circulation. pulse Vibrating sensation or sound that is associated with expansion and contraction of the arteries as blood is propelled through them.

pulse oximetry A technique that uses a sensor placed on a digit, an earlobe, the forehead, or the bridge of the nose to determine oxygen saturation and pulse rate. Pulse oximetry actually combines two physical techniques: (1) the spectrophotometric technique, which is used to determine a patient's percent arterial oxyhemoglobin; and (2) optical plethysmography, which is used to estimate the pulse rate.

**pulse pressure** The difference between the systolic and diastolic pressure.

**pulsus paradoxus** A systolic blood pressure that is more than 10 mm Hg lower during inspiration than during expiration.

#### Q

qualitative Measures the quality of something rather than its

quantitative Measures the quantity of something rather than its quality.

#### R

ramp A comfort feature incorporated in many noninvasive pressure-targeted ventilators that allows an incremental rise in set pressures over a set period of time; most often used in conjunction with the *delay time control*.

Ramsay Sedation Scale A graduated single-category scale used to assess the level of sedation in an individual receiving sedation. recruitment maneuver Denotes activating an intentional transient increase in transpulmonary pressure to open unstable airless alveoli.

relative humidity The actual or absolute amount of humidity in a gas compared with its maximum carrying capacity at that

temperature, calculated as a percent. Relative humidity (absolute)/ (maximum capacity)  $\times$  100.

rescue therapy A life-threatening event requiring nonsurgical treatment.

residual volume The volume of air in the lungs after a maximum exhalation.

resistance Frictional forces associated with ventilation due to the anatomical structure of the conductive airways and the resistance to gas flow through the airways, and the tissue viscous resistance of the lungs and adjacent tissues and organs as the lungs expand and contract.

**respiration** The movement of gas molecules across a membrane. **respiratory alternans** Alternation between using the diaphragm to breathe and the accessory muscles of respiration; an indication of end-stage respiratory muscle fatigue.

**respirometer** A device used to measure breathing variables such as tidal volume and vital capacity.

respite care Allowing caregivers of a ventilator-assisted individual to have an opportunity to rest and relax by providing another caregiver to care for the patient.

retrograde To direct or turn backward.

rocking bed A motorized bed that moves continuously in a longitudinal plane. Expiration is assisted when the head is in the down position and the abdominal contents and diaphragm are moved by gravity toward the thorax (cephalad).

#### 9

scalar A way to specify the waveforms for pressure, flow, and volume that are graphed against time (e.g., pressure, flow, volume scalars). The resulting waveform is referred to as a *scalar*, sedatives Used to reduce anxiety and agitation and to promote sleep and anterograde amnesia.

silent chest Term used to describe the absence of audible breath sounds in a patient experiencing a severe asthma exacerbation. It is characterized by the absence of wheezing due to severe airway obstruction.

**simethicone agents** A nonprescription agent that reduces the surface tension of gas bubbles in the stomach.

single-circuit ventilator A ventilator in which the internal pneumatic circuit allows the gas to go directly from its power source into the patient.

spontaneous breaths A breath or inspiratory gas flow that is started by the patient (patient triggered) and tidal volume delivery is determined by the patient (patient cycled). With spontaneous breaths, the amount of volume and/or pressure delivered is based on patient demand and not by a preselected amount set on a ventilator. static compliance/static effective compliance Compliance measurement obtained during conditions of no gas flow. Compliance is equal to a volume change divided by a pressure change. status asthmaticus A severe and prolonged asthma episode that is poorly responsive to adrenergic agents; associated with decreased airway diameter due to bronchospasm, increased mucous plugging, and inflammation of the airway. Signs and symptoms of potential respiratory failure may be present.

stroke index Stroke volume divided by body surface area. stroke work Cardiac work; calculated by using mean blood pressure multiplied by the stroke volume multiplied by a correction factor. superinfections Infections that develop during drug treatment for another infection, caused by a different microorganism that is resistant to the treatment used for the first infection.

Swan-Ganz catheter A multilumen, balloon-tipped, pulmonary artery catheter originally designed by Swan, Ganz, and colleagues. system compressibility See tubing compliance for a description of system compressibility.

systemic vascular resistance The afterload the left ventricle must overcome to eject blood into the aorta and systemic circulation.

#### Ť

tachycardia Heart rates in the adult greater than 100 beats/min. threshold resistor A device that provides a constant pressure throughout expiration regardless of the rate of gas flow; used in the exhalation line of a ventilator. The exhaled air proceeds unimpeded through the resistor until pressure falls to a preset value (PEEP). At that time, the exhaled gas flow stops and the system pressure is maintained.

thrombolytic therapy Drug therapy directed at dissolving a clot (e.g., administration of streptokinase or urokinase to dissolve an arterial clot in a patient with an acute myocardial infarction resulting from clots in the coronary vessels).

**thrombotic mediators** Chemical substances produced by the body that cause an abnormal vascular condition, resulting in a clot developing inside a blood vessel in the body.

time constant The product of compliance (C) and resistance (R). time cycling When the ventilator ends inspiration after measuring a specific time that has elapsed during the inspiratory phase. time triggering The beginning of inspiration initiated by a ventilator when it detects that a certain period of time has elapsed. Time is commonly based on a rate or frequency control setting. tracheoesophageal fistula A congenital malformation resulting in a tubelike opening between the trachea and esophagus.

tracheomalacia Erosion of the tracheal wall, often associated with excessive pressure from an endotracheal or tracheostomy tube cuff, which reduces effective blood flow through the tracheal wall, resulting in injury to the tissue.

**train-of-four monitoring** An electrophysiological technique used to assess the effectiveness of neuromuscular blocking agents. An electrical current consisting of four impulses is applied to the peripheral nerve over 2 seconds, and the muscle contractions (twitches) produced provide information about the level of muscle paralysis.

**transairway pressure** The difference between airway pressure and alveolar pressure.

transcutaneous monitoring A noninvasive method of indirectly assessing ABGs. Unlike pulse oximetry and capnography, which rely on spectrophotometric analysis, transcutaneous monitoring uses modified blood gas electrodes to measure the oxygen and carbon dioxide tensions at the skin surface.

**transpulmonary pressure** The difference between alveolar pressure and pleural pressure.

**transpyloric** Across the pyloric region of the stomach. **transrespiratory pressure** The difference between airway opening pressure and body surface pressure ( $P_{TR} = P_{awo} - P_{bs}$ ). **transthoracic pressure** The difference between alveolar pressure and body surface pressure; also called *trans-chest wall pressure*. **trigger variable** The phase variable that begins inspiration. **tubing compliance** ( $C_T$ ) System compressibility; reflects the amount (in milliliters) of gas compressed in the ventilator circuit for every

centimeter of water pressure generated by the ventilator during the inspiratory phase. ( $C_T = \text{Change in volume divided by change in pressure } [\Delta V/\Delta P]$  in mL/cm H<sub>2</sub>O).

#### U

**upper airway pressure** Term used to describe airway opening pressure.

upper inflection point A point of significant change in the upper slope of a static pressure—volume curve at the end of lung inflation near total lung capacity (TLC). The change indicates a point at which large numbers of alveoli are being overinflated.

user interface The dials, knobs, controls, and touch screen devices used by the ventilator operator to determine how the ventilator will function.

#### V

ventilation The movement of air into and out of the lungs. ventilator-associated pneumonia (VAP) Pneumonia that develops 48 hours after a patient has been placed on mechanical ventilation. ventilator flow sheet A regularly performed check of the patient—ventilator system, usually done by the respiratory therapy staff; includes patient assessment data, monitored information, and ventilator parameters or parameter changes. Can be handwritten or computer based and is usually performed every 2 to 4 hours, unless an unusual event requires earlier checking.

vital capacity (VC) The total amount of air that can be exhaled after a maximum inspiration. The sum of the inspiratory reserve volume, the tidal volume ( $V_T$ ), and the expiratory reserve volume. volume-controlled ventilation Mechanical ventilatory mode in which a specific tidal volume is set and delivered for each breath. volume cycled Inspiration ends when a preset volume is delivered to the patient.

volume limiting A maximum volume set by the clinician that is set and cannot be exceeded.

**volume triggering** When the ventilator detects a small drop in volume in the patient circuit during the latter part of exhalation and begins inspiration.

**volutrauma** A form of lung injury associated with excessive volume delivery by a ventilator, resulting in tissue injury at the alveolar level.

#### W

weaning The process of discontinuing ventilation and liberating the patient from the ventilator.

## Z

**zero end-expiratory pressure** (**ZEEP**) A baseline pressure of zero during the expiratory phase of mechanical ventilation.

for

Note: Page numbers followed by "f" indicate figures, "t" indicate tables, and "b" indicate boxes.

۸	Acute respiratory distress syndrome	Adults
AADC Con American Acceptation for	(ARDS), 47b, 117–118, 261–262	acute care ventilators for, 377–378
AARC. See American Association for	AECC definition of, 263t	acute respiratory failure in, indications for
Respiratory Care		invasive mechanical ventilation in,
Abdominal distention, 351	Berlin definition of, 264t	
ABG. See Arterial blood gas	case study on, 119b	55b
Abnormal hemoglobin, 168b	categories of, 266	cardiac output of, 200
Abnormal right atrial pressure, values and	clinical scenario, 118b, 279b	critical-care ventilator for, 377
patterns, causes of, 202b	computed tomogram with, changes in,	high-frequency oscillatory ventilation in,
Absorption atelectasis, 247–248, 333	263–265	497—498
Accessory muscles	conditions associated with, 117b	mechanically ventilated, with artificial
of breathing, 2b	diagnostic criteria for, 117b	airways, endotracheal suctioning of,
usage, 333	guidelines for, 117–118	226b
Accidental lavage, source of, 107b	as heterogeneous disorder, 266-267	mechanical ventilatory support in, 50t
ACCP. See American College of Chest	improving oxygenation and management	NIV indications, symptoms and selection
Physicians	of, 244–285	criteria for, 373t
Acid-base factors, in weaning, 408	as inflammatory process, 265-267	noninvasive positive pressure ventilation
Acidosis, untreated, 48	inflammatory response in, chemical	in, indications and contraindications
Acinetobacter, 287–289	mediation in, 266b	for, 56b
ACPE. See Acute cardiogenic pulmonary	long-term follow-up on, 268	resting heart rate of, 200
edema	lung-protective strategies in, 267-268,	weaning and extubation of, physiological
Acquired airway lesions, 450	267b-268b	parameters for, 401t
Activated alarms, algorithms for	lungs	Adult ventilators, tidal volume delivery,
troubleshooting of, 358f	normal vs., 266-267	111
Actual delivered volume, set volume	region creation of, 259f	Aerobic gram-negative bacilli, 287-288,
versus, 38	management of	288b
Actual flow waveform, shadow trigger and	with HFO, case study on, 478b	Aeroneb Professional Nebulizer System,
shape signal comparison, 335f	protocol for, 276f	medication delivery by, 506
Acute asthma, initial ventilator settings,	on mechanical ventilation, 260t	Aerosol delivery, 506
114b	medical management of, 119	factors influencing, 227f
Acute cardiogenic pulmonary edema	noninvasive positive-pressure ventilation	heated humidifiers affecting, 229
(ACPE), 119–120	in, 371	during mechanical ventilation, 507-509
case study on, 120b	pathophysiology, 263, 264f	in noninvasive ventilation, 384
causes of, 119b	PEEP/F <sub>I</sub> O <sub>2</sub> levels with, 271b	factors affecting, 384b
_	pressure-volume curves, 144f, 269f	ventilator-related factors, 228t, 229b
NIV in, 371, 372b	pressure-volume loops in, 268–275, 269f	Aerosol-generating devices, types of,
Acute care facility, transport of mechan-	prone positioning in, 276–278, 277f	228–232
ically ventilated patients within,	recruitment maneuvers in, 271–275,	Aerosolized bronchodilators, delivery of,
238-239	271b—272b	229
Acute care setting		Aerosolized medication, delivery of, 107
decisions made in, evidence-based criteria	static pressure-volume curve, 268, 270f	Aerosols
for, 46–47	vertical gradient in, 267	_
noninvasive positive-pressure ventilation	weighing, 501	administration, 226
in, 370–372, 370b	Acute respiratory failure (ARF), 47–48	circuit-related factors, 229
patient selection criteria in, 373–375,	case study on, 49b	deposition, 230b
374b	definition of, 47–48	patient-related factors, 229
Acute care sites, 420	indications of, 50t	Afterload, 193
Acute head injury, clinical scenario, 117b	patient history and diagnosis of, 48-51	Agitated patient, case study on, 304b
Acute hypercapnic respiratory failure, 48	physiological measurements, 51–54	Airflow
Acute hypoxemic respiratory failure, 47	Acute status asthmaticus, case study on,	limitation of, 463–464
severity of, indicators of, 54b	464b	monitoring, 185
Acute lung injury, 47b	Acute ventilatory failure, 48	Air leak
APRV settings in, weaning, 497t	Acute ventilatory insufficiency, 55b	identification of, 340f
Acute-on-chronic respiratory failure, 55	Adaptive lung ventilation (ALV), 398	indication, 158f
Acute pancreatitis, case study on of, 326b	Adaptive support ventilation, 395, 398	Air, mechanical delivery of, 494
Acute renal failure, laboratory evaluation	Added mechanical dead space, 130, 130f,	Airtight garments, for negative pressure

130b

of, 236

ventilation, 432f

Air trapping, 99, 330—333, 331f—332f auto-PEEP and, 159, 159f	Alarms (Continued) function of, alteration of, 364	APTR. See Airway pressure transmission ratio
representation of, 105f	inspiratory-to-expiratory ratio indicator	ARDS. See Acute respiratory distress
Airway occlusion pressure (P <sub>0.1</sub> ), 402	and, 356	syndrome
graphic representation of, 402f	levels of, 108b	ARF. See Acute respiratory failure
Airway pressure, 3, 3f	situations, 353-356	Arginine vasopressin, 316
curve	Allen test, modified, 135b	Armature, position of, 26
assist ventilation, 35f	ALV. See Adaptive lung ventilation	Arterial blood gas (ABG)
using inspiratory pressure support, 396f	Alveolar dead space, increased, 218, 219b	analysis of, 48, 449
measurements of, 183–184	Alveolar distending pressure, 3	goals, adjusting settings, 502-503,
on mechanical ventilation, 183f	Alveolar filling, 330f	502b-503b
monitoring of, 130-134, 131b	Alveolar minute ventilation, 177, 177f	kidney function and, 317
transmission of, to pleural space, 260	Alveolar oxygenation, 47b	sample, obtaining, 214
waveforms of, tracing illustration of, 203f	Alveolar plateau, 171–172	Arterial blood, pressure measurements,
Airway pressure release ventilation	Alveolar pressure (P <sub>alv</sub> ), 3, 3f, 13, 151	effect, 201f
(APRV), 41, 79, 79f, 472, 472f, 493	P <sub>plat</sub> and, 183b	Arterial catheter, insertion and main-
advantages of, 494–495	Alveolar-to-arterial oxygen tension	tenance of, 196b
airway pressures and, 495	$(P_{(A-a)}O_2)$ , 256	Arterial oxygen content, calculation of, 54b
clinical scenario of, 497b	Alveolar ventilation ( $\dot{V}_A$ ), 47b	Arterial oxygen saturation, pulse oximetry
with curves, 495f	calculation of, 130b	and, 167
disadvantages of, 495	final alveolar ventilation, 130, 131b	Arterial partial pressure of carbon dioxide
discontinuation of, 497	monitoring of, 130	(P <sub>a</sub> CO <sub>2</sub> )
high pressure, setting, 495–496	reductions in, 48	factors affecting, 214f
high time, setting, 496		pH and, 256
	Ambient light, pulse oximeter and, 169	•
initial settings for, 495–496	American Association for Respiratory Care	reduce, during high-frequency oscillatory ventilation, 503b
low pressure, setting, 496	(AARC)	
low time, setting, 496	bronchoscopy assistance, 234b	rise in, 503
names of, 493–494, 494b	clinical practice guidelines for	Arterial partial pressure of oxygen (P <sub>a</sub> O <sub>2</sub> ),
pressure-time curve, and flow-time curve	endotracheal suctioning, 226b	50t
during, 494f	mechanically ventilated patient, in-	elevated, 53
pressure-time waveforms, CPAP and, 493f	hospital transport of, 239b	mean airway pressure and, 313
settings, 159, 159f—160f	recommendations from, 399b	$P_aO_2/F_1O_2$ , 256
settings, example of, 497t	American College of Chest Physicians	ratio, use of, 54
ventilation, compared with, 494–495	(ACCP)	$P_aO_2/P_AO_2$ ratio, use of, 54
Airway pressure transmission ratio	guidelines for liberation from mechanical	Arterial PO <sub>2</sub> , 256
(APTR), 203	ventilation, 412, 413b	Arterial to end-tidal CO <sub>2</sub> tension gradient
Airway resistance, 6, 185	recommendations from, 399b	$(P_{(a-et)}CO_2), 256$
determination of, case study on, 8b	American Thoracic Society (ATS), 372	Arterial to maximum end-expiratory PCO <sub>2</sub>
effects of, 311	guidelines for liberation from mechanical	difference, 175, 175f
equation of, 6b	ventilation, 412, 413b	Arterial-to-venous oxygen content differ-
increased, 7, 48b	γ-Aminobutyric acid (GABA) receptor	ence, 257
increased, high peak pressures from, 314,	complex, 301	Artificial airway
315f	Amplitude, 499–500	complications of, 339–341, 341b
measurement of, 7–8	Analgesia, monitoring of, 300-301, 300t,	cuff leak in, algorithm, 139f
monitoring of, 141–142	300b	mechanically ventilated adults with,
quantifying the degree of, 51	Analgesics, 299–308, 299b	endotracheal suctioning of, 226b
reduction in, 313	practices of, 300	reducing work imposed by, 334–335
Airways	Anatomical dead space (V <sub>Danat</sub> ), 130	removal of, 399b, 403-404
clearance, during mechanical ventilation,	Anatomical shunts, 205	secretion clearance from, 221–226
221	Anesthesia, 300b, 302	Artificial intelligence systems, 398
collapse, 105f	strategies and protocols for, 399b, 410	Ascending ramp, 93, 148f
gas flow through, 504	used in mechanically ventilated patients,	Ascites, 351
management of, equipment for, 427b	304b	Assist/control (A/C) pressure-controlled
opening pressure (P <sub>awo</sub> ), 3, 3f	Anterograde amnesic effects, 301	ventilation, 463, 464f
problems in, 349–350	Antibiotics	Assist-control pressure curve, 36f
causes of, 349b	"bimodal" effect of, 296	Assisted breaths, 43, 65
protecting patient's, 55b	inappropriate use of, 288, 288b	Assisted ventilation, 69-70
Alarms, 107-109, 108b	regimens, algorithm of, 292f	Assist pressure curve, 35f
activation of, 133	Apnea alarms, 108, 356	Asthma, 113–114, 371
algorithms for troubleshooting of, 358f	usage, 108	acute exacerbation of, mechanical
additional, 356	APRV. See Airway pressure release	ventilation in, 113b
apnea, 356	ventilation	case study on, 51b, 464b
common situations in, 353-356	Aptaér Heliox Delivery System, 506f	clinical scenario, 57b-58b, 114b
failure of, 109b, 133b	mode of operation of, 506	guidelines for, 114

Asthma (Continued)	Barotrauma (Continued)	Breath (Continued)
NIV in treatment of, 371	volutrauma and, 323–324	types of, 43, 43b, 44f
severe, clinical scenario, 505b	Baseline ABG, unavailability of, 104	case study on, 65b
Asynchrony, 157b, 335, 348-349	Baseline pressure, 12–13, 12f	volume-cycled ventilation, 38
case study on, 305b	exhalation end, 13f	Breath delivery, 29-45
cycle, 157-158, 158f	expiration and, 40	modes of ventilation and, 64-67
flow, 157–158, 157f	setting of, 96–100	timing of, 67
trigger, 157, 157f	Baseline variable, 33	type of, 64–65
Atelectasis	expiratory phase, 40-43	worksheet for reviewing, 81f
avoidance of, 88	Bellows	Breathing
lung region creation, ARDS and, 259f	bag-in-a-chamber, 21-23	defining, 32f
mask CPAP for, 261	volume device, usage of, 6f	equation of motion and, 30, 30f
mean airway pressure and, 248-249	Bennett ventilators, 39b	flow-controlled, 32
occurrence of, 495	Benzodiazepine, 301-302	nomogram, 89f
prevention of, 47b	effects of, 301	pressure-controlled, 32
Atelectrauma, 321, 324-325	reversal, 301	spontaneous, 73
Atmospheric pressure, 3	potency of, 301	time-controlled, 32
Atracurium, 306	Bias flow, 500	ventilator maintenance of, 32f
Atracurium besylate (Tracrium), 304b	Bicarbonate	volume-controlled, 32
Atrial natriuretic factor, 316	administration of, 114	work of, disorders that increase, 48b
Atrial pressures, 201–202	for metabolic acid-base imbalances,	Bronchodilator therapy
pressure tracing of, 201f	329-330	evaluation of, case study on, 232b
Atropine, administration of, 233-235	Bilevel positive airway pressure (BiPAP),	patient response to, 232, 232f
Audible alarms, 107	43, 43f, 43b, 75–76	Bronchomalacia, 456
activation of, 133	manufacturer names for, 76b	Bronchopleural fistulas, 11
Augmented minute ventilation, 78	in pediatric patients, 455-457	Bronchopulmonary dysplasia, 465
Aura CPAP system, 434f	ventilation, initial settings for, 99	Bronchoscopy
Aura nasal interface, 434f	Biotrauma, 325	assistance, AARC clinical practice
Automatic tube compensation, 40, 393,	Biot respirations, 49	guidelines for, 234b
395—397	BiPAP. See Bilevel positive airway pressure	usage, 233
advantages of, 396b	BiPAP Vision, 376–377	Bronchospasm, 350
arguments against, 396-397	Bird Mark 7 (pneumatically powered ven-	Bubble CPAP (B-CPAP), 453
summary of, 397	tilator), 18, 19f	Bubble humidifiers, usage of, 295
using closed-loop control, 395	Bleeding, occurrence of, 197	
Automode, 397	Blood gases, noninvasive measurements of,	C
Auto-PEEP, 13, 63, 330–333, 330f–331f,	167-170	Capnograph contours, 172-175, 174f
359	Blood oxygenation, decreased, measures of,	Capnography (capnometry), 170–177
air trapping and, 105f, 159, 159f	267b	capnograph contours in, 172–175,
case study on, 106b	Blood pressure, 134–135	174f
definitions of, 104b	PEEP study and, 254	chemical methods in, 170-171
dynamic hyperinflation and, 350–351	ventilator changes in, 311b	clinical applications of, 172-175
effect on ventilator function, 332	Body position	clinical practice guideline for, 172b
expiratory flow pattern in, 466f	change in, 351	during intubation, 175b
expiratory hold and, 41	during PPV, importance of, 275–279	physiological considerations in, 171-172
identification of, 331–332, 331f–332f	Body suit, 431	172f
measurement of, 331–332, 331f–332f	Body surface area (BSA)	volumetric capnometry, 175-177, 176f
Braschi valve in, 331	calculation of, 86	Capnometry, 170-177
methods of reducing, 332–333	cardiac output and, 204	Carbon dioxide (CO <sub>2</sub> ), 2
occurrence of, 330	Body temperature, 135	elimination of, 495
physiological factors that lead to, 330–331	Body verses, 431	measurement of, 170
presence of, 104, 129, 335 static compliance with, measuring, 332	Body wrap, 431 Bonnet fixation, 452f	monitoring, application, 205
tidal volume and, 88	Boyle's law, 4	narcosis, 220b
Auto-Trak sensitivity system, 376	Bradycardia, 200	presence of, 510-511
Autoriggering, 34, 157, 157f, 335	Braschi valve, 331, 332f	rebreathing of, 376, 377b
Average volume assured pressure support	Breath	trending, production, 177, 177f
(AVAPS), 376	phases of, 33–43	Carbon dioxide production ( $\dot{V}CO_2$ )
(1171110), 570	phase variables of, 33–43, 34b	increased, 219
_	premature breath cycling, case study on,	clinical scenario, 219b
B	38b	Carboxyhemoglobin, 167f, 168, 168b
Bag-in-a-chamber (bellows), 21–23	sculpturing of, 74	smoke exposure, 168b
β-Agonists, larger dose of, 230b	sloping, 74	Cardiac arrhythmias, occurrence of, 223
Balloon flotation catheter, positioning, 201	sounds, 135	Cardiac dysrhythmias, development of, 110
Balloon-tipped, flow-directed catheter, 197	assessment of, 112b–113b	Cardiac index
Barotrauma	PEEP and, 255	calculation of, 204

case study on, 204b

occurrence of, 113

Cardiac output (Q), 204–205, 257 adult, 200	Cerebral perfusion, mechanical ventilation on, 315–316	Chronic obstructive pulmonary disease (COPD) (Continued)
factors influencing, 193	Cerebral vessels, carbon dioxide as vaso- dilator of, 220	auto-PEEP and, 336f
measurements, 204 Cardiac tamponade, 322	Chemical capnometers, 171f	clinical scenario, 58b, 112b—113b
effect, 311	use of, 170–171	history of, initial patient assessment, 112b—113b
Cardiac transmural pressure, calculating,	Chemical mediators, 325b	initial ventilator settings, 112b–113b
312b	Chemokines, 325b	mechanical ventilation, guidelines,
Cardiac work, 206–207	Chest	111–112
Cardiogenic pulmonary edema, 350,	cuirass, 369	triggering difficulty, case study on, 332b
371–372	percussion, 232–233	VC-CMV settings, 112b—113b
ARF associated with, 55-56	physical examination of, 135	Chronic respiratory failure, treatment of,
Cardiopulmonary Venturi, double-circuit	radiograph, 112b-113b, 225b	431
ventilator example, 21-23, 23b	respirator, 369f	Chronic restrictive disorder, clinical
Cardiovascular disorders, long-term	shell, 431	scenario on, 58b
mechanical ventilation and, 421b	Chest-abdominal paradox, 335	Chronic stable chronic obstructive pulmo-
Cardiovascular factors, in respiratory	Chest cuirass, 431, 431f	nary disease, 372
failure, 400b	Chest injury, hemodynamic monitoring in,	Circuit disconnect, case study on, 133b
Cardiovascular function, compensation in,	207b	Circuit leaks, 352
311, 311b	Chest radiographic evaluation, 449	Circuit tubing, condensate, 107b
Cardiovascular instability, 55b	Chest wall	CircuVent ventilator circuit adapter, 108f
Cardiovascular principles, review of, 193	deformities of, 48b	Cisatracurium, 306
Cardiovascular stabilization, 110	transpulmonary pressures and, 323b	Cisatracurium besylate (Nimbex), 304b
Cardiovascular system, fentanyl, effects on,	trauma, work of breathing and, 51	Cleft palate, 451
303	Chest wall compliance	Clinical Pulmonary Infection Score (CPIS),
CareFusion AVEA, 493–494	change, 140	290—291
clinician control and, 41	effects of, 312	Clinical shunt, calculation of, 253b
CareFusion Infant Flow SiPAP System,	on lung recruitment, 273–274	Clinical stability, 420–421
453, 453f	protection from overdistention and, 323b	Closed-circuit technique, 221
CareFusion LTV 1200 ventilators, 93b, 428	"Chest-wiggle factor" (CWF), 499	Closed head injury, 115–117
Caregiver skill performance, assessment	change, 501	clinical scenario, 117b
sheet for, 425f	checked, 501	mechanical ventilation for, 116b
Catheter	Cheyne-Stokes respirations, 49	Closed-loop control mode, 395–398
arterial, 196b	CHF. See Congestive heart failure Children, 448	Closed loop systems, 19—20, 20b, 21f
placement, 197—198 positioning, 198	bilevel positive airway pressure in,	Closed-loop ventilation asynchrony, 338, 338f
proximal end of, connection, 222	455–457	Closed-suction catheters (inline suction
pulmonary artery, 197	continuous positive airway pressure in,	catheters), 223, 224f
complications associated with, 199t	455—457	indications for, 224b
insertion sites of, 198, 198t	high-frequency ventilation for, 475b	CMV. See Continuous mandatory
placement of, 197–198	mechanical ventilation	ventilation
position of, West's zone relationship in,	with artificial airways, endotracheal	Coanda effect, 20f
199t	suctioning of, 226b	Colonization, conditions and risk factors
rupture associated from, risk factors of,	indications for, 458b	of, 288b
200, 200b	normal blood pressures and heart rates in,	Comfort, respiratory zone of, 398
in zone 3 position, 199, 199b	200t	Communication, difficulty in, case study
Catheter-associated PA rupture, risk fac-	respiratory distress in, 449	on, 438b
tors, 200b	ventilation of	Community-acquired pneumonia, 371
Centers for Disease Control and Pre-	follow-up and evaluation for, 426b	Compliance (C), 5-6, 6b
vention (CDC), 289	indications for, 458	changes in, 143b
Central hypoventilation syndromes, 421	selection criteria for, 422b	dynamic, 140-141
Central nervous system (CNS), depression,	Choanal atresia, 451	monitoring of, 140-144
301	Chronic assisted ventilator care units, 420	nonexistent/low, 138-139
Central nervous system disorders, 48–49,	Chronic care setting	respiratory rate, oxygenation, and
48b	NIV in, 370b, 372–373	inspiratory pressure (CROP) index,
long-term mechanical ventilation and,	patient selection criteria in, 374–375,	402
421b	374b	static, 6, 6b, 140
Central venous lines, 197	Chronic disorders, NIV indications, symp-	case study on, 8b
Central venous pressure (CVP), 193, 197, 201, 201b	toms and selection criteria for, 375t Chronic hypoventilation, symptoms of,	Compressible volume, 89, 130
catheter, insertion of, 197	372b	Compressors (blowers), 23–24
increase in, 310	Chronic obstructive pulmonary disease	Computed tomography, terminology of, 266b
monitoring, 135	(COPD), 55b, 111–112	Congenital heart disease, 451
Cerebral hemorrhage, from head injury,	acute exacerbation of, 370–371, 371b	Congestive heart failure (CHF), 119–120
48-49	air trapping in, 99	clinical scenario, 58b, 120b, 279b—280b

Congestive heart failure (CHF)	Conventional mechanical ventilation	Deep sedation, 300b
(Continued)	(CMV), 457–474	Deep sulcus sign, 322
guidelines for, 119-120	pressure-time curve contrasting tidal	Deescalating antibiotic therapy, 291, 293b
PEEP and, 260	variations, 502f	Deflation point, 269–270
treatment of, 120b	Conventional ventilation	Dehydration, test for, 58b
Congregate living centers, 420	lung-protective strategies in, 472–474,	Delay-time controls, 376
0 0		•
Conscious sedation (moderate sedation),	473t, 474b	Deoxygenated blood, drainage of, 205
300b	returning to, 503	Depolarizing agents (succinylcholine),
Consolidation, 266b	Conversion system, 23–26	304b, 305
Constant flow, 93, 150b	COPD. See Chronic obstructive pulmonary	Depressant drugs, 48b
versus descending ramp, 93	disease	Derecruitment maneuver, 275
Constant-flow volume ventilation, flow-	Coronary blood flow, with positive-	Derived variables, 185-186
time curve for, 337f	pressure ventilation (PPV), 311	Descending ramp, 93
Constant minute ventilation, with	Cough/coughing	versus constant flow, 93
changing alveolar ventilation, 78t	assessment of, 112b-113b	waveform, 99
Continuous aspiration of subglottic	assisted, 434-435	Dexmedetomidine, 302
	CPAP. See Continuous positive airway	Diaphragm
secretions (CASS), 225, 294, 294b,		
295f	pressure	electrical activity, monitoring of, 510–514
Continuous gas flow, during expiration, 41	Crackles, 135	function, monitor, 510
Continuous mandatory ventilation (CMV),	Cranial vault, 115	history of, 510
68–70, 69b	Critical opening pressure, 8	pacing of, 433
advantages, risks, and advantages of, 74t	Cuff deflation, 436	positions of, 327f
Continuous positive airway pressure	Cuff inflation	Diaphragmatic activity, assess, 510
(CPAP), 63, 73	device, 137b	Diastole, 193
apparatus, stabilization, 452	minimum leak and minimum occlusion	Diazepam, 301, 301b
applications of, 249–250, 451–453, 452b	techniques for, 134b	intravenous administration of, 301
complications of, 434, 454	techniques, case study on, 134b	Digital on/off valve, 26, 27f
	Cuff leak	Direct ARDS, 266
conventional, 452–453		
devices, technical aspects of, 249	resolution of, algorithm for, 139f	Discharge plan, components of, 423b, 426b
excessive, 362	test, 404	Disease
goals of, 249	Cuffless endotracheal tubes, 435–436	process of, patient selection and, 420–421
indications for, 251, 450b	use of, 465	reversibility of, 54-55
infant prongs for, 452f	Cuff, mechanical problems associated with,	Disinfection, procedures for, 440-441
initial pressure for, 453	341b	Disposable peak flowmeters, 53f
introduction to, 248-250	Cuff pressure	Distal ischemia, 196
levels of	accuracy (improvement), cuff inflation	Distress, drug-induced, 351
range of, 433	device, 137b	Documentation
selection of, 251–257	high, 138	importance of, 128b
noninvasive nasal, in neonates, 450–454	measurement of, 136–138, 137b	of patient-ventilator system, 125–128
for obstructive sleep apnea, 433–434	Posey Cuffalator device for, 136f	"Do Not Intubate" patients, 373
	syringe, manometer, and three-way	Double-circuit ventilator, 21–23, 23f
in pediatric patients, 455–457		
positive end-expiratory pressure (PEEP)	stopcock for, 137f	Double triggering, 512
and, 42-43, 42f	Cuirass, chest, 431, 431f	Dräger Evita, 493–494
with a rate, 454	Current generation portable ventilators,	Dräger Evita XL, time-cycled ventilators,
systems, 433–434	428, 428b	38-39
to regulate gas flow, 452	Curves. See Waveforms	Drager V500, clinician control, 41
terminology, 249	Cushing response, 116	Dräger ventilator, 338
use of, 451	Cyanosis, causes of, 170b	Drinker, Phillip, 369
Continuous suction tubes, 225	Cycle asynchrony, 157–158, 158f, 337–338	Drive mechanisms, 23
Continuously variable decelerating	Cycle variable, 33	Drive to breathe, measurement of, 402
waveform, 150	Cycling mechanism (cycle variable), 38–40	Driving pressure, 132
	Cystic fibrosis, 261, 372–373	Drug delivery, MDI and, 506
Contractility, 193	Cytokines, 325b	
Controlled ventilation, 69, 69b	Cytokines, 3230	Drug-induced distress, 351
mechanical, receiving, 186-187		Drug overdose, clinical scenario on, 57b
pressure curve, 34f	D	Dry gases, inhalation of, 106f
Control mode, 34	Datex-Ohmeda, Inc, 506	Dual-control mode, 468-472
volume, 467	Dead space, 130	PRVC dual-control mode, 470b
Control panel (user interface), 18, 20-21,	_	Dual-lumen catheters, 197
22f	anatomic dead space, 130	Dubois body surface chart, 87f
Control system, 18	increase in, 53, 327	Durable medical equipment (DME), 423
Control variable, 31, 31b, 43b	mechanical dead space, 130, 130b	Dyes, dysfunctional hemoglobins and,
targeting pressure as, 65–66, 66b, 68f, 69b	ventilation, 176b	168–169
targeting volume as, 65, 65b, 66f, 66b	Decannulation, 435	Dynamic characteristic (dynamic com-
	tracheal buttons and, 435-440	pliance) (C <sub>D</sub> ), 131, 140–141
Conventional CPAP, 452-453	Decremental PEEP, recruitment and, 274	phance, (CD), 131, 140 141

Dynamic compliances, 185-186	Erosive esophagitis, 429	Extubated patients, invasive mechanical
Dynamic effective compliance, 140	Escherichia coli, 287–288	ventilation in, weaning from, 406b
Dynamic hyperinflation, 48b, 331, 350-351	Esophageal graphics, 160, 160f	Extubation, 482–483
Dynamic pressure element, 196	Esophageal pressure (Pes), 3, 3f, 336f	equipment and procedure for, 405b
Dynamic P-V loops, 143b	curves in, 512f	failure, factors of, 404b
Dysfunctional hemoglobins, 168–169	flow in, 512f	noninvasive positive-pressure ventilation
Dyspnea, sudden onset of, 47	pressure in, 512f	after, 405
	Eucapnic breathing, maintenance of, 220	physiological parameters for, 401t
E	Evidence-based weaning, 398	readiness test, 483b
Early-onset pneumonia, 286-287	Evita XL, 509	risks associated with, 404
EBUS-TBNA, 233	Exacerbation, of asthma, 504	Eyes, damage to, 341b
ECG. See Electrocardiogram	Exclusion criteria, 501	
Edema, lung region creation, ARDS and,	Exercise, 408–409	F
259f	Exhalation end	False pressure readings, 133b
Edi catheter	baseline pressure, 13f	Family education, 423-424
characteristics and placement of,	pressure at, 13	Fatal tracheal-innominate artery fistula,
510-512, 511f	Exhalation, single-breath CO <sub>2</sub> loop of	225
example of, 511f	inspiration and, 176—177, 177f	Fentanyl, 303, 303b
specifications, 511t	Exhaled nitric oxide, monitoring, 177–178	administration of, 303
waveform, 511f	Exhaled tidal volume, 89	effects of, 303
Edi waveform, sinusoidal appearance of,	measurement of, flow transducer in, 6f	Fentanyl citrate (Sublimaze), 303
511	Expiration	Fiberoptic bronchoscopy
EEP. See End-expiratory pressure	accessory muscles, 2b	adapter used during, 235f
Ejection fraction (EF), 193, 206	continuous gas flow during, 41	flexible, 233-235, 234b
Elastance, 5	definition of, 40	usage of, 291
Electrically activated speaking devices, 436	negative end-expiratory pressure (NEEP),	Fick principle, 204, 204b-205b
Electrically powered ventilators, 18, 18b	40, 41f time-limited, 41	Final alveolar ventilation, 130, 131b
Electrocardiogram (ECG), 134	Expiratory cycle, gas flow, 6–7	Final ventilator setup, parameters,
Electromagnetic interference, 364	Expiratory cycle, gas now, 6 7 Expiratory flow, pattern	103-104
Emphysema	flow-time waveform of, 331f	F <sub>I</sub> O <sub>2</sub> , See Fractional concentration of
interstitial, 322f	prolonged, 466f	inspired oxygen
subcutaneous, 322	Expiratory gas flow, factors affecting, 97b	First-generation portable volume
End-exhalation, auto-PEEP, 105f	Expiratory hold (end-expiratory pause), 41	ventilators, 427-428, 428b
End-expiratory pause (expiratory hold), 41	Expiratory limb, coaxial construction, 507f	Fitting gauge, for nasal mask, 379f
End-expiratory pressure (EEP), 131–132,	Expiratory muscle aids, 434–435	Flail chest, work of breathing and, 51
132b	Expiratory phase	Flexible fiberoptic bronchoscopy, 233–235
End-inspiratory pause, 40, 95	attention, 40	234b
Endobronchial ultrasound, 233	baseline variable, 40–43	Flip-flop valve (beam deflection), example
End of exhalation, pressure at, 13, 13f	Expiratory positive airway pressure	of, 20f
Endotracheal intubation, 55b	(EPAP), 375	Flow
Endotracheal suctioning	initiation of, 99	adjustment of, 92b
AARC clinical practice guidelines for,	Expiratory retard, 41-42, 41f	asynchrony, 157–158, 157f, 336, 337f
226b	Expiratory time, 462–465	case study on, 92b
methods of, 221b	tidal volume and, interrelation of, 91b	cycling, 39
Endotracheal tube (ET), 249–250	time constants and, 9	breath termination and, 460
care for, 140	Expiratory valve, 230	during pressure support ventilation,
changer, 138f	unseated or obstructed, 361-362	161–162, 161f, 162b
cuffs, management of, 136–140	Expired air, CO <sub>2</sub> and, 171-172	prevention of, 134
mechanical problems with, 341b	Expired tidal volume (V <sub>Texh</sub> ), 133f	delivery, graphs, 94f determination of, 92
passive humidifiers (heat-moisture exchangers), placement of, 107b	External gas source, technical problems	measurements of, 184–185
removal of, AARC clinical practice	associated with, 230	monitor lines, 131b
guideline for, 406b	External pneumatic circuit, 23	occurrence, 131b
selection, changing, and suctioning of, 294	additional components of, 24f	patterns, 92–95, 93f
size, relationships of, 334f	adjuncts used with, 24b	pressure, volume, and time relationship,
tidal volume, measurement of, 129f	basic elements of, 23b, 24f	148, 148b
Endotracheal tube-associated pneumonia,	External respiration, 2	scalars, 148–150, 149f
224	Extraalveolar air, 321-323	setting for, inadequate, 352, 353f, 358
End tidal carbon dioxide partial pressure	Extracorporeal membrane oxygenation	tidal volume and, relationship, 91–92,
$(P_{et}CO_2)$ , dependence, 172	(ECMO), 484	91b
Enteral feeding, 294	Extrinsic PEEP (PEEP <sub>E</sub> ), 13	triggering, 459f
EPAP. See Expiratory positive airway	addition of, 129	zero, 155b
pressure	definitions of, 104b	Flow chop, 463–464
1	Extuincia vyoult 196	· · · · · · · · · · · · · · · · · · ·

Extrinsic work, 186

Flow-controlled breathing, 32

Equation of motion, 30, 30f, 31b

561

Flow-cycled ventilation, 39, 39f	Gas(es) (Continued)	Helium-oxygen (heliox) (He/O <sub>2</sub> )
Flow limiting, 37	gravity, impact, 277	(Continued)
Flow resistor, 250	heating of, 509	therapy
Flow-through tubes, equations describing,	system leaks, 38	cost and gas consumption during,
504b Flow-time curve, problem, 362f	transport mechanisms of, 478, 479f	505-506
Flow transducer, 6f	trapping. <i>See</i> Air trapping Gas delivery	gas flows during, 505b
Flow triggering, 34–35, 36f	system, changes in, 161f	Helium-oxygen (heliox) (He/O <sub>2</sub> ) delivery devices for, 505–506
response, 104, 104b	to-and-fro motion, 11	
Flow-volume (F-V) loop, 340f, 355f,	Gas flow, 2, 504, 505b	system manufactured, 506-507, 506f-507f
362f	expiratory, factors affecting, 97b	modified nonrebreathing mask for, 506f
components of, 151, 154f	rate of, 92, 92b	technical considerations in, 508–509, 509b
indications, 362f	regulation of, 452	Helium, properties of, 504b
Flow waveforms, 98f	schematic illustration of, 393f	Helmet, 379–382, 381f
studies, summary of findings from, 95b	Gastric distention, positive-pressure	Hemodynamic changes
various forms of, 148f	ventilation and, 317	renal response to, 316
Fluid balance, 236	Gastrointestinal bleeding, 295	in respiratory diseases, 209t
Fluidic gas principles, use of, 453	Gastrointestinal function, mechanical	Hemodynamic data, 255f, 256–257
Fluidic ventilators, 18 Fluid intake, excessive, 236	ventilation effects on, 317	Hemodynamic measurements, obtaining,
	Gastroprotective agents, 288	195–200
Fluid logic (fluidic) pneumatic mechanisms components of 20f	Gastrostomy tube, 424	Hemodynamic monitoring, 192–211
nisms, components of, 20f Fluid pressures, 196	Gel-filled nasal masks, 380f	after open-heart surgery, 207b in chest injury, 207b
Fluid status, evaluating, 236b	Geographical assessment, 423 Glasgow Coma Score, 116b	clinical applications of, 207
Forced expiratory volume in 1 second	Glossopharyngeal breathing, 434	efficacy of, 193
(FEV <sub>1</sub> ), 52–53	Gradients, definition of, 2, 4t	indication for, 192
Fowler position, 55	Ground glass opacification, 266b	invasive, 193
Fractional concentration of inspired	"Grunting", 448–449	potential risks of, 193
oxygen (F <sub>I</sub> O <sub>2</sub> ), 256	Guillain-Barré syndrome, clinical scenario	systems for, 195–196
adjustment of, 104, 247	on, 57b	Hemodynamic parameters, 208t–209t
equation for, 104	, and the second second	Hemodynamic profiles, interpretation of,
selection of, 103-104, 247-248	ш	200-207
titration of, 104	H	Hemoglobin
in ventilator patients, evaluation of,	Haloperidol, 302	abnormal, 168b
246-247	action of, onset, 302	dysfunctional, 168-169
ventilator settings, 103-104	Handwashing, 293–294, 293b	types of, 167f
Fractional hemoglobin saturation, 168	Hayek Oscillator, 435 Head injuries	Hemothorax, work of breathing and, 51
Frank-Starling mechanism, 193, 310	acute, clinical scenario, 117b	HFJV. See High-frequency jet ventilation
FRC. See Functional residual capacity	initial ventilator settings, 117b	HFO. See High-frequency oscillation
Freestanding systems, spontaneous CPAP	mechanical ventilation, indications for,	HFOV. See High-frequency oscillatory
with	116b	ventilation
circuitry for, 250	Healthcare-associated pneumonia (HCAP),	HFPPV. See High-frequency positive pres-
using fluidic gas principles, 453	286–287	sure ventilation
French (Fr) sizes, 197	Heart rate, 134–135, 200	High cuff pressure, 138
Frequency, 465–466	Heated humidifiers, 106-107, 106b-107b	High-frequency flow interruption, 476
control, 34	affecting aerosol delivery, 229	High-frequency jet ventilation (HFJV), 11,
Full face mask, 381f	Heated-wire flow-measuring device, 509	477–478
concerns with, 379–380	Heat-moisture exchanger (HME), 107, 108f,	High-frequency oscillation (HFO)
sizing gauge for, 381f	438b	assistance by, 40
Full (oronasal) mask, and helmet, 379–382, 381f	ability of, 295	recruitment maneuver, use of, 500b
Full ventilatory support, 64	aerosolized medication delivery, 107	technical aspects of, 498
Functional hemoglobin saturation, 168	contraindications for, 107b	High-frequency oscillatory ventilation
Functional residual capacity (FRC), 6f, 13f	placement of, 107b	(HFOV), 11, 476–477, 477f–478f in adult, 497–498
adequacy of, 47b	Helium-oxygen (heliox) (He/O <sub>2</sub> )	amplitude, 499–500
decrease in, 96–97	aerosol delivery, 506, 506f	bias flow, 500
shunt result in, 254f	clinical scenario, 505b, 507b-508b	designs of, 497
increased, 202	disorders treated with, 503b	exclusion criteria of, 501
maintenance of, 448–449	equations describing flow-through tubes,	frequency, 500, 500b
	504b	high-frequency ventilation method, 498
c	mechanical ventilation and, 503-504,	indication of, 501
G Cas(as)	503b-504b, 507-508	initial control settings of, 499–501
Gas(es) distribution of	mixture of, 404, 503	inspiratory time percentage of, 500
effects of mechanical ventilation on,	and NIV, 509 noninvasive positive pressure ventilation,	monitoring, assessment, and adjustment
327–328	493	of, 501–502

High-frequency oscillatory ventilation (HFOV) (Continued)	Homecare ventilators (Continued) portable, 377	Indirect calorimetry critical care concept, 183b
oxygenation during, 502	SIMV mode in, 428b	formulas used during, 182b
patient assessment during, 501b	Homeostasis, maintenance of, 47	measurements
proposed, 497	Hospital-acquired pneumonia (HAP),	metabolic, clinical practice guideline
receiving, 501	286—287	for, 181b
settings of, 500b, 501	HT70 ventilator, 429f	obtaining, 181
step to reduce PaCO <sub>2</sub> during, 503b	Humidification, 106-107, 106f	overview of, 180-183
tidal volume, amplitude, and frequency,	devices, hazards and complications	technical considerations in, 180-183, 180f
503b	associated with use of, 340b	Indirect Fick method, 205
transition from, 501	during noninvasive ventilation, 378, 378b	Infant Flow Pressure Generator, 452f
Vyaire 3100B, 501b	Humidifiers, 441	Infant Flow SiPAP System, 453, 453f
waveform for pressure-time and, 500f	Humidity deficit, 107	Infants
High-frequency percussive ventilation	Hydrodynamic pressure, 196	abdominal surgery on, 467
(HFPV), 476	Hypercapnia	Apgar scores of, 457–458
schematic of, 477f	conditions seen with, 49t	cardiothoracic surgery on, 467
High-frequency positive pressure ven-	recognizing, 48	congenital heart disease, 451 CPAP in
tilation (HFPPV), 475—476 High-frequency positive ventilation	untreated, 48 Hyperinflation	problem solving, case study, 250b
(HFPV), 11	dynamic, 331	use of, 451
High-frequency ventilation (HFV), 11,	PEEP and, 260b	extubation in, 482–483
474–482	periodic, 109–110, 109b	high-frequency oscillatory ventilation in,
contraindications and complications of,	Hyperkalemia, clinical and ECG changes	management of, 480–482, 481f–482f
475	and, 328b	high-frequency ventilation for, 475b
indications for, 475	Hypermetabolic states, examples of, 182,	nasal CPAP for, 505
for infants and children, 475b	182b	prongs, for CPAP, 452f
management strategies for, 480-482	Hyperventilation, 321, 329	prophylactic therapy for, 483
method of, 498	case study on, 216b	rescue therapy for, 483
physiology of, 478-480, 479f	Hypocapnia, sustained severe, 329	ventilation for, follow-up and evaluation
technique, 475	Hypokalemia, clinical and ECG changes	for, 426b
High peak pressures, from increased	associated with, 329b	weaning in, 482-483
airway resistance, 314, 315f	Hypometabolic states, examples of, 182,	Infasurf, 483
High-pressure alarms, 354-355, 355f, 355b	182b	Inflation hold, 314, 314f
activation of, 133	Hypoventilation, 48b, 328-329	inspiratory pause, 40, 40b
common causes of, 354b	disorders and agents associated with, 48b	positive-pressure ventilation with, 40f
triggers of, 354	increases in P <sub>a</sub> CO <sub>2</sub> , 220	Inflection point, 143
High pressure, setting, 495–496	Hypovolemia, relative, 236	Infrared spectroscopy, 171, 171f–172f
High tidal volume delivery, 363	Hypoxemia	Inhaled nitric oxide therapy, 484, 484b
High time, setting, 496	conditions seen with, 49t	Initial patient assessment, 124–146
High-volume/low-pressure cuff, 138f, 224	definition of, 245	clinical laboratory tests for, 128b
Hi-Lo Evac endotracheal tube, 225, 225f	levels of, 245b lower limits of, 333	Initial ventilator settings, 85–102 acute asthma, 114b
Home(s) assessment of, 423	mask CPAP for, 261	based on pulmonary disorder, 121t
discharge to	recognizing, 48	head injury, 117b
family issues in, 424–426	treatment for, 54, 54t	neuromuscular disorder, 115b
plan for, components of, 426b	untreated, 48	patient situations, 111
preparation for, 422–424	Hypoxemic respiratory failure, 371	during pressure ventilation, 96
invasive mechanical ventilation at,	Hypoxia	for specific patient situations, 111
alternatives to, 430-434	clinical and ECG changes and, 328b	during volume-controlled ventilation,
mapping electrical circuits in, 423b	definition of, 245	86-95
mechanical ventilation in, ancillary	types of, 245b	Inline suction catheters (closed-suction
equipment and equipment cleaning for,	Hysteresis, 155b	catheters), 223, 224f
440-441		Innominate artery, rupture of, emergency
modifications in, 423	I	treatment for, 349b
therapy, adjustment to, 456b	Iatrogenic hyperventilation, 115–116	Inspiration
ventilation, equipment selection for,	intentional, 219–220, 219b–220b	accessory muscles, 2b
426-428	Ideal body weight (IBW)	airway expansion, 6f-7f, 7
ventilator-dependent patients in, 420	calculation of, 88b	beginning of, 34–35
respiratory care plan equipment	tidal volume and, 88b	cycle variable, 33
checklist for, 427b	Ileus, 429	cycling mechanism (cycle variable), 38–40
ventilator equipment at, guidelines for	Imposed WOB, determination of, 334	delivery, common methods of, 31b factors, control and measurement, 31–32
disinfecting, 441b Homecare ventilators, 428b	Inadvertent PEEP, 330	flow-cycled ventilation and, 39, 39f
examples of, 427–428	Incisura, 200	flow, zero, 154, 155b
CAMILLIO 01, 12/ 120	Indirect ARDS, 266	1011, 2010, 101, 1000

Inspiration (Continued)	Intermittent abdominal pressure ventilator,	J ·
limit variable during, 35–38	432-433	Jejunostomy tube, 424
flow limiting, 37	Intermittent mandatory ventilation (IMV),	Jet mixing, 478
pressure limiting, 36, 37f	72-73, 315, 315f, 393	,
volume limiting, 37	advantages, risks, and advantages of, 74t	V
pressure-cycled ventilation, 39-40	system for, home use of, 428	K
set volume versus actual delivered volume,	Intermittent positive pressure breathing	Ketoacidosis, 217
38	(IPPB)	Kinetic therapy, 295
single-breath CO <sub>2</sub> loop of, 176-177, 177f	history of, 67	Klebsiella pneumoniae, 287–288
time-cycled ventilation, 38-39	use of mask or mouthpiece in, 370	
trigger variable, 34-35, 34b	Intermittent positive pressure ventilation	L
ventilation model in, 30-31	(IPPV), 370	Laminar flow, 504
ventilator control functions during, 31b	history of, 67	Laryngeal cough reflex, narcotics and, 235
volume-cycled ventilation and, 38	Internal maximum safety pressure, 38	Laryngeal injury, from long-term ven-
Inspiratory cycle percent, 75	Internal pneumatic circuit, 21–23	tilation, 430b
Inspiratory flow, 92–95, 313–314, 313f	Internal respiration, 2	Larynx, damage to, 341b
setting of, 335	Interstitial emphysema, development of,	Late-onset pneumonia, 286–287
in time-cycled ventilator, 92b	322f	Leaks, 352, 358
Inspiratory hold, 40	Intracranial pressure (ICP)	checks for, 352
Inspiratory limb, coaxial construction, 507f	elevated, 259	Left atrial pressure (LAP), 201
Inspiratory pause, 38, 40b	increased, 49, 115	Left ventricular dysfunction, PEEP effects
inflation hold and, 40, 40b	mechanical ventilation on, 315–317	in, 119b
setting of, 132f	Intrapleural pressure (P <sub>p1</sub> ), 3, 3f, 202	Left ventricular end-diastolic pressure
during volume ventilation, 95—96 Inspiratory positive airway pressure	positive-pressure ventilation and, 310f spontaneous inspiration and, 310, 310f	(LVEDP), 193
(IPAP), 43f, 375	Intrapulmonary pressure, 3, 3f, 13	right ventricular (RV) dilation and, 311 Left ventricular function, altered, 310–311,
presence of, 42f	Intrapulmonary shunts, occurrence of,	311f
settings of, 456–457	205	Left ventricular stroke work, calculation of,
Inspiratory pressure, 461–462	Intrathoracic pressures, positive-pressure	206
Inspiratory pressure-volume curve, 273f	ventilation and, 310, 310f	Left ventricular stroke work index
Inspiratory rise time control, sloping or	Intravascular line, fever and, 196-197	(LVSWI), 206
ramping, 161, 161f	Intrinsic PEEP, 13, 63, 330	Length-tension relationship, 193
Inspiratory time (T <sub>I</sub> ), 462–465	definitions of, 104b	Light, ambient, pulse oximeter and, 169
tidal volume and, relationship, 91b, 92	tidal volume and, 88	Light-emitting diode (LED) technology,
time constants and, 9, 463b	Intrinsic work, 186	advances in, 169
Inspiratory time percentage(T <sub>I%</sub> ), 500	Intubation	Limit variable, during inspiration, 35-38
Inspiratory-to-expiratory ratio, 314, 314b,	avoiding, heliox, 504-505, 504b	Linear drive piston, 25b-26b
462-465	capnography during, 175b	Lips, damage to, 341b
calculation of, 91-92	resistance values for, 7b	Liver function, mechanical ventilation
case study on, 92b	without ventilation, 56	effects on, 317
indicator for, alarms and, 356	Invasive hemodynamic monitoring, 193	Long-term acute care hospitals, 420
tidal volume and, relationship, 91-92	Invasive mechanical ventilation	Long-term care sites, 420
Inspiratory waveform, control, overview of,	home alternatives to, 430–434	clinician familiarity with, 412
32–33, 32f	switching to, 384b	for prolonged ventilation, 412
Inspiratory WOB, 330	Invasive positive pressure ventilation	Long-term mechanical ventilation (LTMV),
Inspired air, CO <sub>2</sub> and, 171–172	(IPPV), 51, 64	419
Inspired oxygen concentration, 466–467	tracheostomy tube for, 421	goals of, 419–420
Inspired tidal volume (V <sub>Tinsp</sub> ), 133f	Invasive vascular monitoring system, 195, 195f	medical conditions appropriate for, 421b
Inspissated secretions, complications of NIV, 385	Invasive ventilation	patient groups requiring, 421b Long-term positive pressure ventilation,
InSure, 451	alternatives to, 55–58	complications of, 429–430
Integrated ventilator, 160, 160f	indications for, 55b	Long-term ventilation, 418–446
Intensive care unit (ICU), 420	noninvasive positive pressure ventilation	additional preparation for, 424
hemodynamic assessment and, 208b	changed to, 56b	complications to the airway in, 430b
oxygen analyzers and, 128	tracheostomy as, 372	discharge and
ventilators, 18–19	weaning from, facilitation, 373	plan for, components of, 426b
control variables, availability, 86	Inverse-ratio alarm, 356	preparation for, 422-424, 422b
end-expiratory pause buttons, 331	Inverse (I/E) ratios, 91–92	family education in, 423–424
Intentional iatrogenic hyperventilation,	Inverse ratio ventilation (IRV), 249b	financial considerations in, 422
219-220, 219b-220b	IPAP. See Inspiratory positive airway	follow-up and evaluation for, 424-426
Interface	pressure	geographical and home assessment for,
establishment of, 110	Iron lungs, 10, 369, 430-431	423
mouthpiece, 372	Isothermic saturation boundary (ISB), 106,	psychosocial factors in, 421-422
Intermediate care sites, 420	106f	units, weaning in, 399b, 412

Long-term ventilator-assisted patients,	Lungs (Continued)	Mechanical dead space (V <sub>Dmech</sub> )
ACCP definition of, 419b	tissue involvement, 48b	(Continued)
Long-term ventilatory support, alternative,	units, 8	considerations, 90–91
sites for, 412b	fast, 9	definition of, 90
Loops, normal, 153–154	filling of, 8f	Mechanical insufflation-exsufflation, 435,
Lorazepam (Ativan), 301–302	slow, 9 ventilation of, 258f	435f
adverse drug interactions of, 301–302 discontinuation, case study on, 302b	model of, 30–31	Mechanically ventilated patients
Low cuff pressure, 138–139	volume of, increase in, 47b	anesthetic agents, usage, 304b
Low-flow (quasi-static) technique, 270	West's zones of, 199t	management of sudden severe respiratory distress in, 349b
Low PEEP, 250	LVEDP. See Left ventricular end-diastolic	neuroleptics, usage, 304b
Low PEEP/CPAP alarms, 355	pressure	nosocomial pneumonias, risk reduction
Low perfusion states, 168	product	methods of, 293b
Low-pressure alarms, 133, 353		opioids, usage, 304b
common causes of, 354b	M	sedatives, usage, 304b
setting of, 108	Machine-triggered breath types, during	Mechanical oscillation, 435
Low pressure, setting, 496	N-IMV, 454—455	Mechanical positive pressure breath,
Low-source gas alarms, 108, 108b	Mainstream sampling devices, 171	airway pressure graph, 12f
Low-source gas pressure alarm, 356	Malnutrition, mechanical ventilation and, 317, 317b	Mechanical ventilation
Low time, setting, 496	Mandatory breath, 43, 64–65	accidental disconnections, 340b
Low-volume/high-pressure cuff, 138f	delivery, patient effort, 353f	acute and chronic complications of, 429f
Lower inflection point, 267	Mandatory minute ventilation (MMV),	in adults and children, with artificial
LP10, 428	20–21, 78, 78t, 393	airways, endotracheal suctioning of,
LTV 1200 ventilator, 377f	advantages of, 397b	226b
Lung injury	description of, 397	airway clearance during, 221
measures, 267b	as weaning technique, clinical studies on,	alarms and, 108b
mechanical ventilation for, 321–327	397	basic terms and concepts, 1-16
from overdistention, 323–324	Manometer	complications associated with, 339b
ventilator-associated <i>versus</i> ventilator-	aneroid, 183	controlled, 186
induced, 321, 321b	usage, 13	conventional, 457–474
Lung-protective strategies, 267–268,	Manual ventilation, 110	discontinuation from, 391–417
267b—268b	Maquet Servo-i ventilator, 94	and equipment, 427b
Lung recruitment	Masimo Signal Extraction Technology	establishing need for, 46–61
case report, 275b chest wall compliance, effects of, 273–274	(SET) pulse oximeter, 168	extrapulmonary effects of, 309–319
function of, 271–272	Mask CPAP, 250	history of, 109b
patient evaluation for, 268	complications associated with, 386t, 434t	indications for, 113b indirect calorimetry during, 181b
potential complications during, 274	Mask discomfort, 384–385	initial connection (first 30 minutes),
Lungs	Mask heliox, 505	128–130, 128b
ARDS, inspiratory pressure-volume curve	Mask pressure, 3, 3f	initiation of, ethical considerations in,
in, 272f	Mask systems, aspects of, 505	56-58
characteristics of, 4-8	Maximum airway pressure, 497	injury during, volutrauma and, 321-327
collapse, pneumothorax and, 322	establishing, 499	on intracranial pressure and cerebral
compliance, 5-6, 6b	wide swings in, 499b	perfusion, 315-316
effects of, 312	Maximum expiratory pressure (MEP), 187	on liver and gastrointestinal function, 317
electron micrograph of, 325f	Maximum inspiratory pressure (MIP), 50–52	measurements, 183
histology of, 264f	device for, 52f	metabolic acid-base imbalances and,
intrapleural pressures and, 310, 310f	measurement of, 187–188	329-330
low/high volume of, 265f	measurement of, alternative technique for,	metabolic acid-base status in, 328-330
mechanics, negative-pressure ventilation	52b	minimizing physiological effects and
and, 10f	Maximum safety pressure, 37–38	complications of, 312-315, 313f
nondependent position of, 279f	McKhann, Charles, 369	mode of, 202
ventilation to, 327	Mean airway pressure (P <sub>aw</sub> ), 92, 131, 185,	nutritional complications during,
normal vs. ARDS, 266–267	466, 499	317—318, 317b
overdistention, 260b	adjustment of, 247-248, 248f	objectives of, 47b
perfusion of, 258f	calculation of, method for, 249b	overview of criteria for, 54–55
pressures and gradients, definition of	$P_aO_2$ and, 313	physician's orders for, 125b
pressures and gradients, definition of, 3–4, 4t	Mean arterial pressure (MAP), 200	physiological terms and concepts, 2
pressure-volume curves, 144f	Mean left atrial pressure (MLAP), 206	pMDIs during, 229—230
protection of, PEEP and, 326	Mean pulmonary artery pressure (MPAP),	potential mechanical failures with, 339b pressure-volume curves, 142f
recruitment, 109, 500b	206	renal effects of, 316–317
regions of, ARDS and, 259f	Measured variables, 185	respiratory status in, 328–330
resistance, 6–8	Mechanical dead space (V <sub>Dmech</sub> ), 130 addition, 130, 130f, 130b	standard criteria for instituting, 54b

Mechanical ventilation (Continued)	Minimum minute ventilation, 78	Nasal mask (Continued)
sudden respiratory distress	Minimum occlusion techniques, 134b	disposable, 379f
causes of, 348b	Minimum PEEP, 250	fitting of, 379f
management of, 349b	Minute ventilation ( $\dot{V}_E$ ), 53	indications for continuous positive airway
SVNs during, 230, 230b	case study on, 88b, 90b	pressure via, 450b
terms used in, 10	demands in, reduction of, 338–339	meeting criteria for, 421
types of, 10–11	determining, 86b	problems with, 384
	0.	Nasal minimask, 379
weaning from, 391–417	display, 129	
work of breathing, reduction of, steps for,	improving, 496	headgear and, 380f
334–339	increase in, 358t	Nasal passages, damage to, 341b
Mechanical ventilators	measurement, respirometer technique for,	Nasal pillows, 379
heliox with, 507-508	129b	headgear and, 380f
medications with nebulizers during, 231b	setting of, 86–87	use of, 385
spontaneous CPAP with, 250	special considerations, 95	Nasal prongs
Mechanical ventilatory support	MIP. See Maximum inspiratory pressure	fit of, 452
for acute respiratory failure, 50t	Mixed acid-based disturbances, 218	indications for continuous positive airway
recognizing need for, 448-449	Mixed-mode ventilation, 461	pressure via, 450b
Meconium aspiration syndrome, 450	Mixed venous oxygen saturation, 205, 257	infant flow and, 452f
Medically stable, term, definition of, 374	Mode asynchrony, 338	use of, 453b
Medtronics Puritan Bennet 840, 94t	Moderate sedation (conscious sedation),	Nasal "sigh" positive airway pressure, in
	300b	
Men, ideal body weight for, calculating,		neonates, 453f, 455
88b	Modified Allen test, performing, 196b	Nasopharyngeal injury, from long-term
Mental status, assessment of, 112b–113b	Molecular diffusion, simple, 479	ventilation, 430b
Metabolic acid-base imbalances, mechan-	Monitoring equipment, 238b	Nasopharyngeal tube
ical ventilation and, 329-330	Morphine, 303	indications for continuous positive airway
Metabolic acid-base status, in mechanical	effects of, 303	pressure via, 450b
ventilation, 328–330	Motor nerve damage, 50	use of, 453b
Metabolic acidosis, 217	Mouth care, 140	Nebulization, provided by ventilator, 231,
respiratory alkalosis, combined, 218b	Mouthpiece, headgear or straps,	231f
Metabolic acidosis, blood chemistry in,	requirement (absence), 382	Nebulizers
330t	Mouth pressure (P <sub>M</sub> ), 3, 3f	impairment, 362-363
Metabolic alkalosis	Multidrug-resistant (MDR) infections, risk	during NPPV, use of, 231–232
acid loss and, 330	factors for, 288b	small-volume, during mechanical
	Multidrug-resistant (MDR) micro-	
blood chemistry in, 330t		ventilation, 230, 230b
respiratory acidosis, combined, 218b	organisms, 287, 287b	NEEP. See Negative end-expiratory
Metabolic carts, 180	Multiple organ dysfunction syndrome,	pressure
Metabolic disturbances, clinical scenario,	265–266, 325	Negative end-expiratory pressure (NEEP),
218b	Multiple organ failure, 265–266, 325	40, 41f
Metabolic factors, in respiratory failure, 400b	Muscle dysfunction, 50	Negative inspiratory force (NIF), 51-52,
Metabolic measurements	Muscle function, impaired, 48b	401-402
clinical applications of, 181-183	Muscles, respiratory, inactivity of, 31	Negative pressure ventilation (NPV), 3-4,
clinical practice guideline for, 181b	Muscle strength, 401-402	430-431
Metabolic monitoring system, major	Myasthenia gravis	airtight garments for, 432f
components of, 180, 180f	case study on, 246b	cuirass shell for, 431f
Metabolic rate, 86	initial ventilator settings, 115b	lung mechanics after, 10f
factors, 181–182	Myocardial ischemia, borderline, 110	use of, 10, 369
	Myocardiar ischemia, bordenine, 110	
Metabolism, increased, 219		Negative pressure ventilators, 19
clinical scenario, 219b	N	Neonatal ventilator
Metered-dose inhaler (MDI)	Nail polish, pulse oximeter and, 169	advancement in, 460
use of, 107	Naloxone hydrochloride, 57b	circuit, schematic for, 459f
ventilator circuit adaptation, 229f	Nasal cannula, for heliox, delivery of, 505	features of, 460b
Methemoglobin, 167f, 168	Nasal CPAP, 250, 505	Neonates, 448–449
Methicillin-resistant Staphylococcus aureus,	applications of, 451–453, 452b	assessment and treatment of, case study
patient case of, 293b	indications and contraindications for,	on, 456b
Microprocessor-controlled ventilators, 129		continuous positive airway pressure in,
Microprocessors, 18	450-451, 450b	indications of, 450b
random access memory (RAM), usage,	in neonates, 450–454, 450b	cuffless ETs in, use of, 465
18-19	Nasal headgear, disposable, 379f	determining effective oxygenation and
read-only memory (ROM), updating,	Nasal high-frequency ventilation, in	ventilation in, 449
, , , , , , , , , , , , , , , , , , , ,	neonates, 455	
18–19	Nasal interfaces, 378-382	extubation in, 451
usage, 7–8	Nasal intermittent mandatory ventilation,	graphic waveform, 461f
ventilators controlled by, waveform	in neonates, 454-455	heart rates for, 200
display capability of, 33	Nasal mask	invasive mechanical ventilation in, clinical
Midazolam, 301, 301b	for CPAP, 433	indications for, 457b
Minimal sedation, 300b	disadvantages of, 378–379	lung disorders, lung- protective ventilation
Minimum leak techniques, 134b	0., 0, 0	strategies for, 473t

Neonates (Continued)	Nocturnal hypoventilation, 373, 373b	Noninvasive ventilation (NIV)
nasal continuous positive airway pressure	Nonbronchoscopic techniques, description	(Continued)
in, 450–454, 450b	of, 291	face or nasal mask, fitting, 110
applications of, 451–453, 452b	Nondependent lung, ventilation to, 327,	indications for, 373
indications and contraindications for,	327f	techniques of, 369–370
450b	Nondepolarizing agents, 305–306	Nosocomial pneumonia
nasal intermittent mandatory ventilation	Nonexistent cuff pressure, 138–139	pathogenic organisms from, 287b
in, 454–455	Noninvasive devices, 431–433	risk, reduction methods of, 293b
nasal "sigh" positive airway pressure in,	Noninvasive nasal continuous positive air-	NPV. See Negative pressure ventilation
453f, 455	way pressure, in neonates, 450–454	Numeric intensity scale, 238f
noninvasive nasal high-frequency ventilation in, 455	Noninvasive neurally adjusted ventilatory	Nurse-driven protocols, 410
•	assist (NAVA), 455 Noninvasive positive pressure ventilation	Nutrition, adequate, 424
noninvasive positive pressure ventilation in, 454–455	(NPPV), 46–47, 55–56, 63–64, 430	Nutritional status, 408–409
patient-triggered pressure-controlled	adjustment of, 382–384	
intermittent mandatory in, 461f	case study on, 383b—384b	0
pediatric ventilatory support, goals of, 450	advantages and disadvantages of, 64b	Obstructed expiratory valve, 361–362
physical examination, abnormalities on,	aerosol delivery in, 384	Obstructive sleep apnea (OSA), 370
450b	factors affecting, 384b	continuous positive airway pressure
respiratory distress in, 448-449	after extubation, 405	(CPAP) for, 433–434
magnitude of, Silverman-Anderson	basic concepts of, 368-390	therapy for, 373
score for, 449f	bilevel PAP and, 99	Occlusion pressure measurements, 188
TCPL/ IMV, asynchrony during, 459	changed to invasive ventilation, 56b	Occult PEEP, 330
transient tachypnea of, 450	clinical benefits of, 370b	Oliguria, 316
ventilators for, features of, 458b	complications of, 384-386	Open-circuit technique, 221
ventilatory support of, indications for,	case study on, 384b	Open-heart surgery, hemodynamic
457-458	contraindications for, 56b	monitoring after, 207b
Neural control, review of, 510	discontinuation of, 386	Open-loop system, 19–20, 20b, 21f
Neurally adjusted ventilatory assist, 472	disorders managed with, 64b	Open reservoir, use of, 395f
alarms and safety features in, 515-516	equipment selection for, 375-382	Operational verification procedure (OVP), 125
electrical activity, monitoring, 510	exclusion criteria for, 374b	Operator settings, incompatible with
evaluating, 516	expiratory positive airway pressure, levels	machine parameters, 356
monitoring of, 509-510	of, 493	Operator's manuals, 364
use of, 514–515	goals of, 370–373	Opioids, 303
ventilation, results of initiating, 516	heliox and, 493	pharmacologic action of, 303
weaning from, 516	humidification issues during, 378	side effects of, 303, 303b
Neurally adjusted ventilatory assist	indications for, 56b, 370–373	reversal of, 303
(NAVA), 35	in acute respiratory failure, 373t	usage, in mechanically ventilated patients
Neuroleptics, 302, 302b	in chronic disorders, 375t	304b
usage, in mechanically ventilated patients,	initiation of, steps for, 382b	Optical shunting, 169
304b	instituting, criteria for, 406b	Optimal PEEP, 251
Neurologic factors, in respiratory failure,	interfaces in, advantages and disadvantages of, 378t	establishment of, 246-248
400b Neuromuscular blocking agents (NMBAs),	monitoring of, 382–384	selection of, 251-257
304b	case study on, 383b	case study on, 257b
case study on, 306b	nasal mask in, meeting criteria for, 421	study of, 252-257
classes of, availability of, 304	nebulizers during, 231–232	performing, 254
monitoring, 305	in neonates, 454–455	Oral cavity, examination of, 349
withdrawal, prolonged paralysis (reasons),	patient selection for, case study on, 383b	Oral interfaces, 382
408	preparation for, 382	Oral mouthpiece, 382f
Neuromuscular disorders, 48b, 50,	selecting the patient interface in, 63–64	Oronasal mask, 381f
114-115	selection criteria for, list of, 373t, 375t	Oropharyngeal decontamination, 295
clinical scenario, 115b	setup for, 382	Oropharynx, damage to, 341b
drugs and, 50	success predictors of, 383b	OSA. See Obstructive sleep apnea
guidelines for, 115	symptoms for, list of, 373t, 375t	Oscillators drive mechanism for, 477f
initial ventilator settings, 115b	termination of, criteria for, 384b	
long-term mechanical ventilation and,	therapy with, complications associated	sinusoidal waveform generated by, 498f
421b	with, 386t, 434t	Overdistention, 321
ventilation in, case study on, 50b	types of, 370	lung injury from, 323–324
Newborn. See Neonates	weaning from, 386	PEEP and, 260b
Nitric oxide, exhaled	Noninvasive respiratory support, 450–457	pressure-volume curve for, 324f
factors affecting levels of, 177b	Noninvasive ventilation (NIV), 294	pressure-volume loop and, 256f
monitoring of, 177–178	clinical benefits of, 370b	protection from, chest-wall compliance
NIV. See Noninvasive ventilation	definition of, 369	and, 323b

567

Overinflation, 96, 359	Patent airway, maintenance of, 48	Peak expiratory flow, 52-53, 53f
OVP. See Operational verification	Patent ductus arteriosus, 451	rate (PEFR), defined, 151
procedure	Patient care team, concerns of, 386	Peak inspiratory pressure (PIP), 12f, 13,
Oxygen	Patient-centered mechanical ventilation,	131, 185, 185b
administration equipment for, 427b	238	adjustment in, 455
analyzers, 128	Patient circuit, 21	changes, examples of, 141t
concentration of, inspired, 466-467	additional components of, 24f	concerns with, 93
delivery, 205, 205b	adjuncts used with, 24b	evaluation of, case study on, 355b
open reservoir to enhance, 395f	basic elements of, 23b, 24f	Peak pressure, 13
to tissues, basics of, 246-248	Patient-circuit leaks, during PSV, 362	alarm activating, case study on, 322b
desaturation of, 372	Patients	pneumothorax and, 322
flow rates of, higher, 376	agitation, case study on, 304b	Pediatric infant ventilators, features for,
toxicity of, 333	appearance of, PEEP and, 254	460b
pulmonary changes associated with,	assessment, case study on, 136b	Pediatric patient. See Children
333b	changing position, 279b	Pediatric ventilator, 458-461
Oxygenation, 114	circuit, accidental disconnections, 340b	advancement of, 460
adequacy of, 403	clinical stability of, 420-421	features of, 458b
adjusting, 496-497	closed head injury guidelines, 116-117	Pediatric ventilatory support, goals of, 450
basics of, 246-248	comfort, improvement in, 383b	PEEP. See Positive end-expiratory pressure
calculation of, equations for, 247b	comfort of, 237-238	Pendelluft, 478-479
continuous monitoring of, 48	confusion and delirium in, 237	Percent leak, 465
data, 255f	effort, control of, 34	Perfusion states, low, 168
determination of, 449	evaluation of, clinical factors in, 400b	Perfusion without ventilation, 205
evaluation of, measures and values in,	information of, 125	Periodic hyperinflation, 109-110, 109b
246t	initial assessment, 112b-113b	Perivascular, 321-322
failure of, 54, 54b	initial ventilator settings for, 111	Permissive hypercapnia, 114, 220
goal for, 502-503	interfaces, 378	circulatory effects of, 220-221
during HFOV, 502	management techniques in, 235	clinical scenario, 221b
inadequate, 352	neuromuscular disorder guidelines, 115	contraindications of, 220-221, 221b
in prone positioning, potential	preparation of, 110	procedures for managing, 220, 220b
mechanisms of, 275-279	problems related to, 349-351	Phase variables, breath phases and, 33-43
Oxygen consumption (VO2), 204	protecting, 347–348	34b
Oxygen content, calculation of, 204	respiratory distress in, 47	Philips Respironics Healthcare V60
Oxygen saturation measured by pulse	safety of, 237	ventilator, 376f
oximetry (S <sub>p</sub> O <sub>2</sub> )	selection of, 420-422	Phrenic nerve, severed, 511-512
assessment of, 112b-113b	criteria for, 373-375	Physical appearance, assessment of,
in ventilator patients, evaluation of,	size, suction levels and, 222t	112b-113b
246-247	sudden distress	Physiological dead space, increased,
Oxygen saturation of arterial blood (S <sub>a</sub> O <sub>2</sub> ),	causes of, 348b	218-219
204	identification of, 348-349, 348b	Physiological positive end-expiratory pres-
Oxygen therapy, hazards of, mechanical	temperature, 135	sure, 96–100, 97b
ventilation and, 333	variability among, 273	Physiological shunt, determination of, 205
Oxyhemoglobin (O <sub>2</sub> Hb), 167f, 168	ventilatory performance of, 401–402	Pilot tube
dissociation curve	Patient-triggered ventilation, 460	cut in, 139-140, 140f
for arterial blood, 169f	Patient triggering, 34-35, 35f, 36b	repair kit, 140f
right shift, acidosis and, 328	case study on, 35b	PIP. See Peak inspiratory pressure
	inadequate sensitivity setting for, 359	Piston-driven ventilator, internal pneu-
P	Patient-ventilator asynchrony, 348, 349b,	matic circuit, example of, 37f
	360, 363f	Pitt speaking tracheostomy tube, 436-437
P <sub>a</sub> CO <sub>2</sub> , See Arterial partial pressure of carbon dioxide	assessment of, 157-158, 157f, 157b, 158f	437f
	detecting, using Edi catheter, 512-513	Plasma renin activity (PRA), 316, 317b
Palv. See Alveolar pressure	examples of, 352-353, 353b	Plateau pressure (P <sub>plat</sub> ), 3, 13, 13f, 40, 131
P <sub>a</sub> O <sub>2</sub> . See Arterial partial pressure of	Patient-ventilator management, methods to	131b, 183, 185b
Oxygen  PAOP, See Pulmonery extery occlusion	improve ventilation in, 213-243	changes, examples of, 141t
PAOP. See Pulmonary artery occlusion	Patient-ventilator synchrony, 335-338	evaluation of, case study on, 355b
pressure  Paradoxical breathing 51 135	improved, 459f	measurement of, 13, 95b, 130f
Paradoxical breathing, 51, 135	Patient-ventilator system, documentation	Pleural space, airway pressure to, trans-
Paralytic disorders, 48b	of, 125–128	mission of, 260
Paralytic drugs, 48b	PC-CMV. See Pressure-controlled con-	Pleura-occupying lesions, 48b
Paralytics, 299–308, 299b, 304b	tinuous mandatory ventilation	Pneumatically powered ventilators, 18-19
Partial ventilatory support, 64 Passive humidifiers, placement of, 107b	PC-IMV. See Pressure-controlled inter-	19b
	mittent mandatory ventilation	Bird Mark, 18, 19f
Passy-Muir valve, 438, 438f	PC-IRV. See Pressure-controlled inverse	Pneumatic circuit, 21-23
patient's experience with, clinical scenario on, 439b	ratio ventilation	external, 23

varying levels of, 203f

Pneumatic circuit (Continued)	Positive end-expiratory pressure (PEEP)	Pressure (Continued)
internal, 21-23	(Continued)	percentage, change in, 465f
Pneumatic flow control valve, digital on/	weaning from, 261, 262t, 262b-263b	scalars, 149f, 151f-153f
off valve, 27f	withdrawal, 262b	triggering, sensitivity level for, 34, 35f
Pneumobelt, 432-433	Positive pressure breath	units of, 3
with positive pressure generator, 433f	upper airway pressure graph, 12f	waves
Pneumomediastinum, 322	volume from, 118f	negative pressure ventilation and, 10f
Pneumoperitoneum, 323	Positive pressure ventilation (PPV), 4,	positive pressure ventilation, impact of,
Pneumotachometer, 52	10-11, 128b	11f-12f
Pneumothorax, 322-323, 350	beneficial effects on heart function in	Pressure augmentation, 76-77
tension, 322	patients with left ventricular	Pressure broadening, 171
work of breathing and, 51	dysfunction, 312, 312b	Pressure-control inverse ratio ventilation,
Polymicrobial infections, 287-288	body position during, 275-279	pressure-time curves for, 493f
Polyneuritis, 311	cardiovascular effects of	Pressure-controlled breathing, 32
Portable homecare ventilators, 377	adverse, 310-311	Pressure-controlled continuous mandatory
Portable pressure-targeted ventilators, 375	factors influencing, 311-312	ventilation (PC-CMV), 70-72, 71f,
limitations of, 375	coronary blood flow with, 311	74t, 471f
Portex speaking tracheostomy tube,	duration and magnitude of, 312	advantage of, 99
436–437, 436f	effects on pulmonary system, 320-345	in children, 461f
Posey Cuffalator device, 136f	endocrine effects of, on renal function,	for COPD, 112
Positive end-expiratory pressure (PEEP),	316	descending ramp waveform and, 99
12-13, 12f, 314, 314f, 462-467, 463f	fluid balance and, 236	with high PEEP level, 274
airway suctioning with, 261	inflation hold with, 40f	with increased PEEP, 274
applications of, 249–250, 253t	and lungs, intrapleural pressures and, 310,	in patient with respiratory acidosis,
physiological factors for, 258f	310f	adjustment, 215b
applied or inadvertent, 202	mechanics and pressure waves associated	scalars, 150, 151f
ARDS vertical gradient and, 267	with, 11f-12f	tidal volume during, 97b
asynchrony, 338	oxygenation in, mechanisms of, 275–279	Pressure-controlled intermittent mandatory
baseline pressure level and, 40	positive end-expiratory pressure (PEEP)	ventilation (PC-IMV)
congestive heart failure and, 260	and, 310	advantages, risks, and advantages of,
continuous positive airway pressure	selection of, 114	74t
(CPAP) and, 42–43, 42f		scalars, 150, 152f
contraindications for, 259	thoracic pump mechanism during, 310	Pressure-controlled inverse ratio ven-
	usage of, 370	tilation (PC-IRV), 71–72
during controlled ventilation, 42f definitions of, 12–13, 104b	Positive pressure ventilators, 19, 21f Postextubation	Pressure-controlled ventilation, 31, 31b,
		33f, 39, 69b
devices, technical aspects of, 249	difficulties in, 404–405	
establishment of, 246–248	laryngospasm, occurrence of, 404	with airflow limitation, 464f
excessive, 338, 362	stridor, 505	assessing overdistention during, 160–161 160f–161f
flowsheet of, example, 255f goals of, 249	Postmyocardial infarction, ventilatory	
g ·	support, 95b	descending waveform, 68f
increased, effects of, 258t—259t, 463f	Postoperative pulmonary complications,	volume-controlled ventilation <i>versus</i> , 150, 150b
indications for, 251, 251b	48b	
initiating, 251	Postpolio syndrome, 434	volume, decrease (clinical scenario),
introduction to, 248–250	Postural drainage, 232—233	216b
left ventricular dysfunction, effects in,	Power input alarm, 356	Pressure control mode, 461–462
119b	Power transmission, 23–26	Pressure control ventilation, 86b
levels of	PPV. See Positive pressure ventilation	initial settings for, 98–99
high, 255f	Preload, 193	PIP and volume evaluation in, case study
selection of, 251–257	Premature breath cycling, case study on,	on, 355b
minimum/low loop, 250	38b	Pressure-cycled inspiration, 75b
optimal, 251	Premature pressure support termination	Pressure cycling, pressure limiting <i>versus</i> ,
physiological effects of, 259–261	(PPST), 467–468	37–38
positive-pressure ventilation and, 310	Pressure	Pressure limiting, 36, 37f
pulmonary effects of, 259–260	baseline, 12–13	pressure cycling versus, 37–38
ranges, 250-251	calculation of, 6b	Pressure manometer, 51–52, 52f
setting, pressure-volume loops in,	definition of, 3–4, 4t	Pressure-regulated volume control
268-275	in positive-pressure ventilation, 10-11	(PRVC), 77, 77f, 99–100
study of	determining, 86b	case study on, 100b
in experimental model involving oleic	driving, 132	inspiratory phase of, 469f
acid injury, 257t	at end of exhalation, 13, 13f	names for, 100t
parameters measured and monitored	equivalents of, 3b	Pressure support, 36
during, 253b	flow, volume, and time relationship, 148,	flow asynchrony, 468f
terminology, 249	148b	flow synchrony, 468f
therapeutic, 251	gradients, 3, 3f	Pressure-supported breath, triggering of
titration of, 159, 159f	limit, 133	nebulizer impairment of,

peak pressure, 13

362-363

569

Pressure support ventilation (PSV), 73–75, 75f–76f, 86b, 394–395, 467–468,	Proportional assist ventilation (PAV), 79–80, 79b	Pulmonary vascular pressure monitoring, with PEEP, 257—258
468f	Proportional solenoid valve, type of flow,	Pulmonary vascular problems, 48b
additional settings in, 74-75, 76f	control valve, 26, 26f	Pulmonary vascular resistance (PVR), 193
flow cycling during, 161-162, 161f, 162b	Proximal airway pressure, 3	calculation of, 193
initial settings for, 98, 98f	PRVC. See Pressure-regulated volume	positive pressure and, effects on, 328, 328f
inspiratory flow termination in, 99b	control	positive pressure ventilation and,
patient-circuit leaks during, 362	Pseudomonas aeruginosa, 287-289	310-311, 311f
time-cycled and pressure-cycled	Pseudooscillators, 476	Pulse oximeter, 167f
inspiration with, 75b	PSV. See Pressure support ventilation	ambient light and, 169
Pressure-targeted ventilation (PTV),	Psychological factors	capability, description of, 168-169
clinical scenario, 216b	in respiratory failure, 400b	case study on, 120b
Pressure-targeted ventilators (PTV),	in weaning, 409	nail polish and, 169
375–377, 376b	Psychological status, 236-237	pulsatile and nonpulsatile components of,
Pressure-time curve, fluctuations in, 363f	Pulmonary angiogram, 351	168f
Pressure-time product, 187-188, 189f	Pulmonary artery (PA)	skin pigmentation and, 169
Pressure-time waveforms, 36, 37f, 42f	bedside catheterization of, 197	Pulse oximetry, 48, 167-170, 167f-168f
with continuous positive airway pressure	catheterization, 197-200, 197f	clinical applications of, 169-170
(CPAP) and, 42f	pressure, 202–204	clinical practice guideline for, 170b
mean airway pressure and, 248f	pressures of, 135, 201-204	physiological and technical concerns for,
Pressure tracing	response to ventilation of, 202f	168-169
of arterial pressure, 201f	tracing, baseline of, 202	Pulse pressure, 200-201
evaluation of, 204b	waveform, systemic arterial waveform	Pulse rate, determination of, 167
of pulmonary artery, baseline, 202	and, 202	Puritan Bennett 840 ventilator, 74-75
Pressure ventilation	Pulmonary artery (PA) catheter, 197	Puritan Bennett 7200 ventilator, fixed flow,
changes, 214-216, 215f	complications associated with, 199t	336
initial ventilator settings during, 96	insertion sites of, 198, 198t	Pursed-lip breathing, 41-42, 97b
inspiratory time, inadequacy of, 359	placement of, 197-198	PVR. See Pulmonary vascular resistance
modes, with volume targeting, initial	position of, West's zone relationship in,	
settings for, 99	199f	R
required setting selection and variables	rupture associated from, risk factors of,	Radford's nomogram, 89f
during, 96t	200, 200b	Rales, 135
tidal volume delivery in, 97-98, 97b	in zone 3 position, 199, 199b	Ramp, 376
Pressure-volume (P-V) curves	Pulmonary artery occlusion pressure	Ramsay Sedation Scale, 300t
bedside measurement of, 142-144, 142f,	(PAOP), 193, 201–202, 201b	Random access memory (RAM), usage,
144f	abnormal values/patterns in, causes of,	18–19
data correlation of, 143t	202b	Rapid shallow breathing index (RSBI)
obtaining, techniques for, 143b	important role of, 201–202	calculation of, case study on, 401b
for PEEP, 246-248	increased, effects of, 259t	for weaning status, 401
Pressure-volume (P-V) loops, 157f, 272f,	wedged position and, 198-199	Rate control, 34
362f, 462f	Pulmonary blood flow	Rat lungs, macroscopic aspect of, 326f
components of, 151, 153f-154f	detection, capnography in, 175	Readiness, assessment of, 399b
PEEP, 159f	effects of mechanical ventilation on,	Read-only memory (ROM), 18–19
slope, positive end-expiratory pressure	327-328	Rebreathing circuit, by Respironics NICO
(PEEP), effect of increasing, 463f	redistribution of, 327–328	capnometer, 205f
spontaneous breaths and, 151, 154f	Pulmonary condition, clinical findings of,	Recruitment-derecruitment, 321
Pressure waveforms, 98f	143t	Recruitment maneuvers, 271-275,
for airway pressure release ventilation, 79f	Pulmonary disorders	271b-272b
various forms of, 148f	initial ventilator settings, 121t	hazards of, 273
Pressurized metered dose inhalers	physical and radiologic findings in, 136t	summary of, 275, 275b
(pMDIs), during mechanical ven-	Pulmonary edema, 350	theoretical model of, 273f
tilation, 229–230	Pulmonary embolism (PE), 351	types of, 274–275
Problem, definition of, 347	as emergency, 351	use of, 500b
Prone positioning, 268, 276–278, 277f	Pulmonary infiltrates, presence of, 289	Reflectance oximetry, 205
contraindications to, 277b	Pulmonary injury sequence (PIS), 474	Rehabilitation hospital, 420
oxygenation in, mechanisms of, 275–279	Pulmonary interstitial emphysema, clinical	Reintubation, 404, 404b
protocol for, 278b	scenario, 477b	Relative humidity, changes in, 106-107,
for respiratory support, 484	Pulmonary mechanics, monitoring, ven-	106b
technical aspects of, 277–278	tilator graphics for, 154–156,	Renal effects, impaired, 317
Prophylactic antibiotics, 296	154f—155f, 155b, 156f	Renal failure/malfunction, 236
Prophylactic therapy, 483	Pulmonary overdistention, from CPAP,	Renal insufficiency, fentanyl (usage), 303
Propofol (Diprivan), 302, 302b	454, 454f	Rescue therapy, 483
hemodynamic effects of, 302	Pulmonary shunt, 248b	Residual volume, 52
onset and duration of, 302	Pulmonary specialty wards, 420	Resistance, 6–8

values for, 8b  Respiration, 2  Respiratory acidosis  adjusting PC-CMV in patient with  (clinical aconario) 215b  weakness 114  Rotary drive piston, 25b–26  Respiratory muscles  inactivity, 31  strengthening of, 409  Saline instillation, normal, 2	
Respiratory acidosis inactivity, 31 adjusting PC-CMV in patient with strengthening of, 409  Saline instillation, normal, 2	25
adjusting PC-CMV in patient with strengthening of, 409 Saline instillation, normal, 2	25
adjusting PC-CMV in patient with strengthening of, 409 Saline instillation, normal, 2	25
(clinical econoria) 215h	
(clinical scenario), 215b weakness, 114 Scalars, 148–150, 149f–152	f
clinical and ECG changes and, 328b  Respiratory quotient, variations in, 180b  normal, 153–154	-
increasing rate (clinical scenario), 215b Respiratory rate term, usage, 147–148	
increasing tidal volume, 215b calculation of, 91 SCCM. See Society of Critic	al Care
metabolic alkalosis, combined, 218b case study on, 90b Medicine	ar care
volume and pressure ventilation changes, minute ventilation and, 53	
214–216, 215f tidal volume and, interrelation of, 91b clearance 221–226, 434–	435
Respiratory alkalosis Respiratory special care units, 420 removal 223	100
clinical and ECG changes associated with, Respiratory status, in mechanical ven-	
329b tilation, 328–330 levels of, 300b	
decreasing rate (clinical scenario), 216b  Respiratory support, adjunctive forms of,  Joint Commission defin	nitions of, 300
metabolic acidosis, combined, 218b 483–484 monitoring of, 300–301,	
during spontaneous efforts, 217b  Respiratory system  practices of, 300	3000, 3000
VC-CMV and PC-CMV changes, mechanics strategies and protocols for	or 399b 410
216-217 assessment of, 183 Sedatives, 299-308, 299b	71, 3770, 110
ventilator-induced, 408t clinical applications of, 185–188 usage of	
volume decrease in pressure-controlled derived variables in, 185–186 for mechanically ventile	ated nationts
ventilation, 217b measured variables in, 185	iteu patients,
Respiratory alternans, 394 pressure gradients, 3f  Selective digestive tract deco	ntamination
Respiratory capabilities, and demands, Respiratory therapy, equipment of, 289  296	intammation,
balance between, 392f Respiratory zone, of comfort, 398 Semirecumbent patient positions and the semirecumbent patient positions are semirecumbent patient positions.	tioning 294
Respiratory care plan, long-term mechan-	-
ical ventilation and, 427b  Respironics NICO capnometer, rebreathing  104–107, 104b, 105f, 10	_
Respiratory diseases, hemodynamic circuit by, 205f Sensor Medics 3100A, 477, 4	
changes in, 209t Respite care, 422  Servo-i	1771
Respiratory disorders, long-term mechan- Resting heart rate, 200  ventilator	
ical ventilation and, 421b  Restrictive thoracic disorders, 372, 372b  main screen in, 513f–5	14f 514
Respiratory distress  Resuscitation bag, 348  during NAVA ventilation bag, 348	
causes of, 3480 Rediction pattern, 2000 "volume control" 513f	011, 3131
management of, in mechanically Retrograde pressures, 193 VS of 338	
ventilated patient, 349b  Reverse Trendelenburg position, 432  Set pressure, 131	
physical signs of, 348f Reynold's number, 504b Set volume, actual delivered	volume and.
recognition of, 4/ Right atrial pressure (RAP), 193, 197,	voidille dila,
severe, evaluation of, in a ventilated 201–204 Severe asthma, clinical scena	rio, 505b
patient, case study on, 351b abnormal values/patterns in, causes of, Severe inspiratory airflow lin	
sudden, clinical scenario for, 350b 202b sure-controlled ventilati	-
Respiratory disturbance, clinical scenario, continuous monitoring of, 201  Severe respiratory distress	1011 (1111) 1011
218b normal ranges in, 201 causes of 349b	
Respiratory drive Right atrium evaluation of, case study of	on, 351b
abnormalities in, 351 catheter advancement in, waveforms from, management of, 349b	,
decreased, central nervous system 1981 signs of 348f	
disorders and, 48 indwelling venous catheter placement, 135 Shadow triggering 335	
Respiratory factors, in respiratory failure, Kight ventricular (KV) alterioad, increase Shallow breathing, 51	
400b in, 310-311 Shape signal, 335, 335f	
Respiratory failure Right ventricular (RV) dilation, 311 Shear stress, 324, 324f, 324b	
acute, 47–48 Right ventricular end-diastolic pressure Shell ventilator, 369	
case study on, 49b (RVEDP), 193 Shikani, 437	
definition of, 47–48 Right ventricular (RV) function, altered, Short binasal prongs, use of	, 454
indications of, 50t 310–311, 311f Shunt	
patient history and diagnosis of, 48–51 Right ventricular pressure (RVP), 197 clinical, calculation of, 25.	3b
physiological measurements, 51–54 direct measurements of, 201 definition of, 205	
cause of, treatment of, 110 Right ventricular stroke work, calculation fraction 205–206	
clinical indications for, 448–449 of, 206 pulmonary, 248b	
definition of, 448 Right ventricular stroke work index Sidestream sampling devices	, 171
disorders and agents associated with, 48b (RVSWI), 206 Sigh/sighing, 109–110, 109b	
etiology of, determining, 400b Kise time, /4 history of, 109b	
Respiratory fluctuations, PA catheter Rise-time control, 3/6 techniques. 274–275	
placements during, 198 Rising exponential curve, 150 Silent aspiration, 224	

Slowtown symbol and exhalition is commendation and exhalition is completed by the cample of, 5f single-breath CO (SBCO) curve description of, 178–176, 176f of impiration and exhalition, 176–177, 176f of impiration and, 421b of impiration and exhalition, 176–177, 176f of impiration and, 421b of impiration and exhalition (SIMV), 73b, 393 of impiration and, 421b of impiration and, 421b of impiration and exhalition (SIMV), 73b, 393 of impiration and, 421b of impiration and exhalition (SIMV), 73b, 393 of impiration and, 421b of impiration and, 421b of impiration and exhalition (SIMV), 73b, 393 of impiration and, 421b of impiration and, 421b of impiration and exhalition and impiration and impiration and exhalition and impiration a	Silverman-Anderson respiratory scoring system, 448–449, 449f	Spontaneous inspiration, intrapleural pressure and, 310f	Super-syringe technique, 144f, 269–270, 269f
SINMV. See Synchronized intermittent mandatory ventilation of six example of, 5f example of, 5f single-breath CO <sub>2</sub> (SBCO <sub>2</sub> ) curve description of, 178–176, 176f of impiration and exhalation, 176–177, 177f upper airway infections and, 235 Stable chronic lung diseases, 421 Stable durating facilities, 420 case study on, 8b measurement of, auto PEEP and, 256 Static pressure, 183 measurement of, auto PEEP and, 332 PEEP and, 256 Static pressure, 183 measurement of, auto PEEP and, 332 Statins, 236–237 curve, 142, 142 loop, features of, 270–271 Stop, features of, 270–	Simethicone agents, 385	Spontaneous modes, 73-75	Supplemental oxygen therapy, 48
mechanics of, 2—4 sumple of, 51 preserving, 494–495 Sing-breath CO <sub>7</sub> (SBCO <sub>2</sub> ) curve description of, 175–176, 176f of inspiration and exhalation, 176–177, Single-circuit ventilator, 21, 22f Sheletal disorders, long-term mechanical ventilation and exhalation pulse oximeter and, 169 Skilled myrain facilities, 420 Skill pigmentation, pulse oximeter and, 169 Status, 256–237 In green facilities, 420 Skill pressure, 183 In page status, 256–237 Single-circuit ventilator, 21, 22f Status, 256–237 St	SIMV. See Synchronized intermittent man-	=	
Sine flow, 93 Sine wave pressure curve, 377 Single-breath CO <sub>2</sub> (SBCO <sub>2</sub> ) curve description of, 175–176, 1767 of inspiration and exhalation, 176–177, 1777 Single-fricuit ventilator, 21, 227 Skeled alboretes, long-term mechanical ventilation and, 4210 Skild narrising facilities, 420 Skild prigmentation, pulse oximeter and, 169 Sleep Ineutabolic rate reduction, associated with, 182 Sleep apnea Sleep apnea Sleep apnea Slep apnea	datory ventilation	mechanics of, 2-4	alteration of, 324-325
Sine was pressure curve, 37f Single-breath CO <sub>2</sub> (SBCO <sub>2</sub> ) curve description of, 175—176, 176f of inspiration and exhalation, 176—177, 177f Single-circuit ventilator, 21, 22f Skeletal disorders, long-term mechanical ventilation and 421b Skilled nursing facilities, 420 Skilled pressure volume (SPV) Status, 236—237 Beep apnea PEEP and, 26- Status 236—237 Single venturi, design of, 47ef Slope control, 161 Small airways, laminar flow in, 594 Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 Troomerns with, 439 Speaking tracheostomy tubes, 436—437 concerns with, 439 Speaking tracheostomy tubes, 436—447 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 403, 403b railure, 3999 recommendation in, 105, 405b prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 105, 405b prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering helion in, 505—506, 5056 prologed, 334 Moracic pump mechanism during, 310 Spontaneous breathing, 2,	Sine flow, 93	example of, 5f	artificial, 480
Single-breath CO <sub>2</sub> (SBCO <sub>2</sub> ) curve description of 175–176, 176f of inspiration and exhalation, 176–177, 177f Single-Circuit ventilator, 21, 22f Stable carbonic lung diseases, 421 Stable compliance (Col.), 6, 6, 140, 186 calculation and, 421b Stable compliance (Col.), 6, 6, 140, 186 calculation and, 421b Stable compliance (Col.), 6, 6, 140, 186 calculation of, 60 sease study on, 8b measurement of, auto PEEP and, 332 PEP and, 261 Static pressure, 183 head, 196 Static pressure volume (SPV) carbonic activation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation and, 421b Months of the calculation of, 60 static compliance (Col.), 6, 6, 140, 186 calculation of, 60 static pressure volume (SPV) carbonic activation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 274 Synchronized intermittent mandatory ventilation (SIMY, 378, 393 disvained inflation, 279 Synch	Sine wave pressure curve, 37f	_	deficiency syndromes, 462
description of, 175—176, 176f of inspiration and exhalation, 176—177, 176f of inspiration and, 421b chronic lung diseases, 421 skelet al disorders, long-term mechanical verillation, and, 421b chronic lung diseases, 421 skile compliance (C <sub>2</sub> ), 6, 6), 140, 186 claulation of, 60 case study on, 8b case study on	Single-breath CO <sub>2</sub> (SBCO <sub>2</sub> ) curve		replacement therapy, 483-484
of inspiration and exhalation, 176—177, 177  lingle-circuit ventilator, 21, 227  Single-circuit ventilator, 21, 227  Single-circuit ventilator, 21, 227  Single-circuit ventilator, 22, 237  Single-circuit ventilator, 22, 247  Single-circuit ventilator, 22, 257  Single-circuit ventilator, 22, 257  Single-circuit ventilator, 22, 257  Single-circuit ventilator, 220  Sin pigmentation, pulse oximeter and, 169  169  Sleep  Metabolic rate reduction, associated with, 182  Status, 226–237  Sleep apme  PETP and, 256  Spydemone, 489  Slatic pressure volume (SPV)  Static pressure vo	-		
Single-circuit ventilator, 21, 22f Skeled al disorder, long-term mechanical ventilation and, 421b Skiled nursing facilities, 420 Skiled pursing facilities,	of inspiration and exhalation, 176-177,	color, 235t	Sustained inflation, 274
Skeletal disorders, long-term mechanical ventilation and, 421b skilled nursing facilities, 420 Skilled nursing facilities, 420 Skin pigmentation, pulse oximeter and, 169 Interpretation, associated with, 182 Interpretation, associated with, 182 Interpretation, associated with, 182 Interpretation, 236–237 Skeep apnea PEEP and, 261 Syndrome, 48b Sliding Venturi, design of, 476f Slope control, 161 Small airways, laminar flow in, 504 Small airways, laminar flow in, 405 Small-avolume nebulizers (SWNs), 228, 295 durain on f, 239 Speaking tracheostomy tubes, 436–437 Small airways, laminar flow in, 405 Speaking tracheostomy tubes, 436–437 Small airways in the state utilization pattern, 182–183, 182b Speech judgetite secretories, apiration of, 207 Subatmospheric pressure, docrease in, 435 Subatmospheric pressure, decrease in,	177f	upper airway infections and, 235	Swan-Ganz catheter, 197
Skeletal disorders, long-term mechanical ventilation and, 421b skilled nursing facilities, 420 Skilled nursing facilities, 420 Skin pigmentation, pulse oximeter and, 169 Interpretation, associated with, 182 Interpretation, associated with, 182 Interpretation, associated with, 182 Interpretation, 236–237 Skeep apnea PEEP and, 261 Syndrome, 48b Sliding Venturi, design of, 476f Slope control, 161 Small airways, laminar flow in, 504 Small airways, laminar flow in, 405 Small-avolume nebulizers (SWNs), 228, 295 durain on f, 239 Speaking tracheostomy tubes, 436–437 Small airways, laminar flow in, 405 Speaking tracheostomy tubes, 436–437 Small airways in the state utilization pattern, 182–183, 182b Speech judgetite secretories, apiration of, 207 Subatmospheric pressure, docrease in, 435 Subatmospheric pressure, decrease in,	Single-circuit ventilator, 21, 22f	Stable chronic lung diseases, 421	Synchronized intermittent mandatory ven-
Skilled nursing facilities, 420 Skin pigmentation, pulse oximeter and, 169 Sleep metabolic rate reduction, associated with, 182 sture, 236–237 Sleep apnea PEEP and, 261 syndrome, 48b Slemp apnea Sleep apnea Sle	Skeletal disorders, long-term mechanical		tilation (SIMV), 73b, 393
Skin pigmentation, pulse oximeter and, 169 169 Sleep metabolic rate reduction, associated with, 182 status, 236—237 Static pressure, 183 head, 196 Static pressure, 183 head, 196 Static pressure volume (SPV) curve, 142, 142f loop, features of, 270—271 Stiff lungs, 254f Stoma, maintenance of, 439—440 Strain gauge pressure transducer, 183, 195—196, 195f Small airways, laminar flow in, 504 Small-volume nebulizers (SVNs), 228, 295 Smoke exposure, 168b Srockety of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436—437 concerns with, 439 Speaking tracheostomy tubes, 435—440 Sportaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505b Sprolaneous breathing, 2, 73 airway pressure during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403h evaluation on, 405, 405b robothems during, 403, 405b failure, 399b recommendation, 404, 405 Sportaneous breaths, 43, 65 pressure-volume lopps and, 151, 154f Smoke exposure, 182 Static pressure- volume (SPV) curve, 142, 142f Usiff lungs, 254f Static pressure-volume (SPV) curve, 142, 142f Stuff lungs, 254f Static pressure-volume (SPV) curve, 142, 142f Stuff lungs, 254f Static pressure-volume (SPV) curve, 142, 142f Stuff lungs, 254f Systemic arterial blood pressure, 135 Systemic arterial pressure, 200—201 direct measurement of, 190 Systemic arterial pressure, 200—201 Systemic arterial blood pressure, 135 Systemic arterial blood pressure, 136 S	ventilation and, 421b	calculation of, 6b	flow, volume, airway pressure and
Steep metabolic rate reduction, associated with, 182 static pressure, 183 head, 196 static pressure, 183 head, 196 static pressure volume (SPV) curve, 142, 142′ loop, features of, 270–271 stiff lungs, 254′ storage, maintenance of, 439–440 small airways, laminar flow in, 504 small volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230b position of, 388f Soncke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Seaking tracheostomy tubes, 436–437 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f specific dynamic action, 182 Specialized continuous suction endotracheal tubes, 295f specific dynamic action, 182 Specialized continuous suction endotracheal tubes, 295f device for delivering heliox in, 505–506, 505b failure, 399b failure, 399b rolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing 43, 405 problems during, clinical signs and symptoms indicating, 403b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b recultation maintenance in, 409–410 spontaneous breathing 43, 65 pressure-covulem (SPV) can an agreement 185 to the size, 222b subtamospheric pressure, tasandurer, 183, 195–196, 1956 transmittenance in, 495 device for delivering heliox in, 505–506, 505b failure, 399b contened between the size (estimation), based on endotracheal tube size, 222b suctioning assessment during, 403, 403b failure, 399b contened between the size (estimation), based on endotracheal tube size, 222b furnation of, 2222–223 hazards and complications of, 223, 223b hazards and complications of, 223, 223b hazards and complications of, 223, 223b furnation of, 349b clinical scenario, 350b management of, 496 clinical scenario, 349b clinical scenario, 349c display, 129 specific vene acava,	Skilled nursing facilities, 420	case study on, 8b	esophageal pressure measurements
Sleep metabolic rate reduction, associated with, 182 metabolic rate reduction, associated with, 182 status, 236—237  Sleep apnea  FEEP and, 261  Sliding Venturi, design of, 4766  Sliding Venturi, design of, 4766  Small airways, laminar flow in, 504  Smoke exposure, 168b  Smoke exposure, 168b  Smoke exposure, 168b  Smoke exposure, 168b  Stroke videx, 504  Smoke exposure, 168b  Stroke work, 205  Stroke videx, 506, 207b  Subacute care units, 420  Subatmospheric pressure, 402  Subatmospheric pressure, 415  Systemic arterial bood prespore, 206  Systemic arterial bood prespore, 135  Systemic arterial bood prespore, 135  Systemic arterial bood prespore, 206  Systemic arterial bood prespore, 135  Systemic arterial bood prespore, 135  Systemic arterial bood prespore, 135  Systemi	Skin pigmentation, pulse oximeter and,	measurement of, auto PEEP and, 332	in, 394f
metabolic rate reduction, associated with, 182 status, 236—237 status, 236—237 curve, 142, 142f status, 236—237 curve, 142, 142f soop, features of, 270—271 stiff lungs, 254f syndrome, 48b store, and 25 strain gauge pressure ravolation (4, 196) syndrome, 48b store, and 25 strain gauge pressure transducer, 183, 195—196, 195f strain gauge pressure transducer, 183, 195—196, 195f strain gauge pressure transducer, 183, 195—196, 195f straw-sipping problem, 105 strain gauge pressure transducer, 183, 195—196, 195f straw-sipping problem, 105 stroke inducer, (51) calculation of, 204 case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 204b stroke victim, case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 49b strok	169	PEEP and, 256	System compressibility, 89
metabolic rate reduction, associated with, 182 status, 236—237 status, 236—237 curve, 142, 142f status, 236—237 curve, 142, 142f soop, features of, 270—271 stiff lungs, 254f syndrome, 48b store, and 25 strain gauge pressure ravolation (4, 196) syndrome, 48b store, and 25 strain gauge pressure transducer, 183, 195—196, 195f strain gauge pressure transducer, 183, 195—196, 195f strain gauge pressure transducer, 183, 195—196, 195f straw-sipping problem, 105 strain gauge pressure transducer, 183, 195—196, 195f straw-sipping problem, 105 stroke inducer, (51) calculation of, 204 case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 204b stroke victim, case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 49b stroke victim, case study on, 49b stroke victim, case study on, 204b stroke victim, case study on, 49b strok	Sleep	Static pressure, 183	
Status, 236—237  Sleep apnea  PFEP and, 261 syndrome, 48b Sliding Venturi, design of, 476f Small airways, laminar flow in, 504 Small-volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230b Dosition of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 Speaking tracheostomy tubes, 436—437 concerns with, 439 Speaking valves, 435—440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Sportaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b Spontaneous breathing trial (SBT), 73, 400, 401b Spontaneous breathing trial (SBT), 73, 400, 401b Spontaneous breathing, 403, 403b failure, 399b recommendation in, 405, 405b problems during, dinical signs and symptoms indicating, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, 403, 403b failure, 402 failure matucer, 439–440 Strain gauge pressure transducer, 183, 59eths, 195 Calculation of, 405 Strake index (SI) Stiff lungs, 254f Stoma, 409 Strake index, 439 Strai	metabolic rate reduction, associated with,	head, 196	
Sleep apnea   loop, features of, 270–271   196–197   PEEP and, 261   Stiff lungs, 234f   Stoma, maintenance of, 439–440   Strain gauge pressure transducer, 183, 195–196, 195f   Small airways, laminar flow in, 504   Small volume nebulizers (SVNs), 228, 295   during mechanical ventilation, 230, 230b   Stroke index (SI)   Streaming, 479, 479f   Stroke index (SI)   Streaming, 479, 479f   Stroke index (SI)   Streaming, 479, 479f   Streaming are delicine (SCCM) NMBA administration recommendation, 305   recommendations from, 399b   Speaking tracheostomy tubes, 436–437   concerns with, 439   Specialized continuous suction endotracheal tubes, 295f   Specific dynamic action, 182   Specific dynamic action, 200, 311b   Systemic hypotension, 200, 31b   Systemic hypotension, 200, 31b   Systemic hypotension, 200, 31b   Systemic vascular resistance (SVR), 26s   Systemic vascular resistance (SVR), 26s   Systemic vascular resistance (SVR), 206   Stroke work, 20-40   Tachycardia, 48b, 200   hypoxemia and, 223   Tank ventilators, 439 –431   Targetic place, as out of a partition of, 221   Tank ventilators, 439 –431   Targetic place, as out of a partition of, 221   Tank ventilators, 439 –431   Targetic place	182	Static pressure-volume (SPV)	
Sleep apnea   loop, features of, 270–271   196–197   PEEP and, 261   Stiff lungs, 234f   Stoma, maintenance of, 439–440   Strain gauge pressure transducer, 183, 195–196, 195f   Small airways, laminar flow in, 504   Small volume nebulizers (SVNs), 228, 295   during mechanical ventilation, 230, 230b   Stroke index (SI)   Streaming, 479, 479f   Stroke index (SI)   Streaming, 479, 479f   Stroke index (SI)   Streaming, 479, 479f   Streaming are delicine (SCCM) NMBA administration recommendation, 305   recommendations from, 399b   Speaking tracheostomy tubes, 436–437   concerns with, 439   Specialized continuous suction endotracheal tubes, 295f   Specific dynamic action, 182   Specific dynamic action, 200, 311b   Systemic hypotension, 200, 31b   Systemic hypotension, 200, 31b   Systemic hypotension, 200, 31b   Systemic vascular resistance (SVR), 26s   Systemic vascular resistance (SVR), 26s   Systemic vascular resistance (SVR), 206   Stroke work, 20-40   Tachycardia, 48b, 200   hypoxemia and, 223   Tank ventilators, 439 –431   Targetic place, as out of a partition of, 221   Tank ventilators, 439 –431   Targetic place, as out of a partition of, 221   Tank ventilators, 439 –431   Targetic place	status, 236–237	curve, 142, 142f	Systemic artery catheterization,
PEEP and, 261 syndrome, 48b Sliding Venturi, design of, 476f Slope control, 161 Small arivaxys, laminar flow in, 504 Small-volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230 Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracknestomy tube, 436–437 concerns with, 439 Speaking tracknestomy tube and, 435–440 Concerns with, 439 Speaking tracknestomy tube and, 435–440 Concerns with, 439 Specialized continuous suction endotracheal trackeal tubes, 295f Desech Ioss of, 436 tracknestomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505 Spontaneous breathing trial (SBT), 73, 400, 401b Spontaneous breathing trial (SBT), 73, 400, 401b Spontaneous breathing, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous CPAP, circuitry for, 250.	Sleep apnea	loop, features of, 270-271	· · · · · · · · · · · · · · · · · · ·
syndrome, 48b Sliding Venturi, design of, 476f Slope control, 161 Small airways, laminar flow in, 504 Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking tracheostomy tubes, 436–437 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Specih loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 assessment during, 403, 403b failure, 399b sudden responsible and control air and turing, 403, 403b assessment during, 403, 405b problems during, clinical signs and symptons indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptons indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptons indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptons indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptons indicating, 403b ventilation maintenance in, 409–410 Spontaneous CPAP, circuitry for, 250.	PEEP and, 261	-	Systemic hypotension, 200, 311b
Slope control, 161 Small airways, laminar flow in, 504 Stroke work, 906, 2979 Stroke index (SI) Calculation of, 204 case study on, 204b Stroke volume (SV), 206 Stroke work, 206, 207b Subacute care units, 420 Subatmospheric pressure, decrease in, 435 Subglottic secretions, aspiration of, 224–225 Substrate utilization pattern, 182–183, 182b Specialized continuous suction endotracheal tubes, 299f Specifile dynamic action, 182 Special grach pattern, 182–183, 182b Specifile dynamic action, 182 Special grach pattern, 182–183, 182b Specifile dynamic action, 182 Special dynamic action, 1	syndrome, 48b		
Small airways, laminar flow in, 504 Small-volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230b position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specific dynamic action, 182	Sliding Venturi, design of, 476f	Strain gauge pressure transducer, 183,	calculation of, 206
Small-volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230b position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speck growing action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b failure, 399b failure, 399b failure, 399b failure, 399b failure, 399b forecommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous CPAP, circuitzy for, 250 Suctions can be tracked for the distress, identification of patient in, 348–349, 348b causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous Supports vena cava, indwelling venous Supports vena cava, indwelling venous	Slope control, 161		normal ranges of, 206
Small-volume nebulizers (SVNs), 228, 295 during mechanical ventilation, 230, 230b position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Speck growing action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b failure, 399b failure, 399b failure, 399b failure, 399b failure, 399b forecommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous CPAP, circuitzy for, 250 Suctions can be tracked for the distress, identification of patient in, 348–349, 348b causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous Supports vena cava, indwelling venous Supports vena cava, indwelling venous	-	Straw-sipping problem, 105	•
during mechanical ventilation, 230, 230b 230b Stroke index (SI)  position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436—437 concerns with, 439 Speaking tracheostomy tubes, 436—440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f concerns with, 439 Specialized continuous suction endotracheal tubes, 295f close of, 436 tracheostomy tube and, 435—440 Speech Spontaneous breathing r. 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505h prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, dinical signs and symptoms indicating, 403b ventilation maintenance in, 409—410 Spontaneous CP&P, circuitry for, 250 spontaneous CP&P, circuitry for, 250 spontaneous CPAP,	Small-volume nebulizers (SVNs), 228, 295	Streaming, 479, 479f	-
230b Stroke index (SI) position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Special loss of, 436 loss of, 436 loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, diciating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, diciating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 problems during, clinical signs and symptoms indicating, 403b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, Spontaneous CPAP, circuitry for, 250 problems during, clinical segns and complications of, 349b certained (SCCM) Sudaden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous Sudabra respiratory distress catheter yellogeneral 135 display, 129  Tachycardia, 48b, 200 hypoxemia and, 223 Tachypnea, 48b "Talking" tracheostomy tube, 437f Tank ventilators, 48b "Taking" tracheostomy tube, 437f Tank ventilators, 48b "Talking" tracheostomy tube, 437f Tank ventilators, 435 Tarkpeardia, 48b, 200 hypoxemia and, 223 Tachypnea, 48b "Talking" tracheostomy tube, 437f Tank ventilators, 48	during mechanical ventilation, 230,		•
position of, 385f Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specified dynamic action, 182 Specified dynamic action, 182 Specialized continuous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, d103h symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 54f Snottaneous CPAP, circuitry for, 250 Smoke exposudo, 204b Stroke volume (SV), 206 Stroke work, 206, 207b Stroke volume (SV), 206 Stroke work, 206, 207b Stroke volume (SV), 206 Subature units, 420 Subature care units, 420 Subature are units, 420 Subature care units, 420 Subature care units, 420 Stroke volume (SV), 206 Subature stretions, sapiration of, 55 Substrate utilization pattern, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—183, 182—			т
Smoke exposure, 168b Society of Critical Care Medicine (SCCM) NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 Concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b sassessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous CPAP, circuity for, 250 Spontaneou	position of, 385f	calculation of, 204	<del>-</del>
Society of Critical Care Medicine (SCCM)  NMBA administration recommendation, 305 recommendations from, 399b Speaking tracheostomy tubes, 436—437 concerns with, 439 Speaking valves, 435—440 concerns with, 439 Speaking adves, 435—440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435—440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409—410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250.	-	case study on, 204b	•
Stroke vorking (Syr), 206 recommendations from, 399b Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b recommendation in, 405, 405b problems during, 403, 403b failure, 399b recommendation, in 405, 405b problems during, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous (PAP, gignitry for, 250) Speaking tracheostomy tubes, 4366 Subatmospheric pressure, decrease in, 435 Substrate utilization of, 305 inactivation of, 305 side effects of, 305 usage of, 305 Suction catheters flexible, 222f Therapitic PEEP, 251 Therapitic PEEP, 251 Therapi	Society of Critical Care Medicine (SCCM)	·	
Stroke work, 200, 200 Subacute care units, 420  Speaking tracheostomy tubes, 436–437 concerns with, 439  Speaking valves, 435–440 concerns with, 439  Specialized continuous suction endotracheal tubes, 295f Specifi dynamic action, 182  Speech loss of, 436 tracheostomy tube and, 435–440  Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310  Spontaneous breathing trial (SBT), 73, 400, 401b  Aution of, 222–225  Suctioning assessment during, 403, 403b failure, 399b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b sudden respiratory distress causes of, 349b Superior vena cava, indwelling venous Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP, gignitry for, 250.		· · · · · · · · · · · · · · · · · · ·	
Speaking tracheostomy tubes, 436–437 concerns with, 439 Speaking valves, 435–440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b problems during, 403, 403b failure, 399b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 5pressure-volume loops and, 151, 5pressu	305	Stroke work, 206, 207b	
Speaking tracheostomly tubes, 435—440 concerns with, 439 Speaking valves, 435—440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435—440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b problems during, 403, 403b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409—410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous (PAP, circuitry for, 250) Substrate utilization pattern, 182—183, 1435 Subglottic secretions, aspiration of, 224—225 Substrate utilization pattern, 182—183, 182b Substrate utilization pattern, 182—183, 182b Substrate utilization pattern, 182—183, 182b Suction catheters, 197 Therapeutic PEEP, 251 Therapist-driven protocols (TDPs), 410 Thermal flow meters, 184—185 Thermodilution catheters, 197 Thoracic pressure-volume relations, patterns of alteration in, 354t Thoracic pump mechanism, 310 Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97—98 display, 129	recommendations from, 399b	Subacute care units, 420	
Speaking valves, 435—440 concerns with, 439 Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435—440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505—506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403—400 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 5peaks of the state of	Speaking tracheostomy tubes, 436-437	Subatmospheric pressure, decrease in, 435	
Speaking valves, 435—440 concerns with, 439  Specialized continuous suction endotracheal tubes, 295f  Specific dynamic action, 182  Speech loss of, 436  tracheostomy tube and, 435—440  Spontaneous breathing, 2, 73  airway pressure during, 495  device for delivering heliox in, 505—506, 505b  prolonged, 334  thoracic pump mechanism during, 310  Spontaneous breathing trial (SBT), 73, 400, 401b  assessment during, 403, 403b  recommendation in, 405, 405b  problems during, clinical signs and symptoms indicating, 403b  ventilation maintenance in, 409—410  Spontaneous breaths, 43, 65  pressure-volume loops and, 151, 154f  Spontaneous CPAP, circuitry for, 250  224—225  Substrate utilization pattern, 182—183, 182b  Succinykleholine, 305  inactivation of, 305  side effects of, 305  usage of, 305  Suction, 305  inactivation of, 305  Therapeutic PEEP, 251  Therapist drive procols (TDPs), 410  Therminal flow meters, 184—185  Therapist drive procols (TDPs), 410  Therapist drive prepare vene	concerns with, 439	Subglottic secretions, aspiration of,	
Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for, 250 Specific dynamic action, 182 Suction, 305 inactivation of, 305	Speaking valves, 435-440		
Specialized continuous suction endotracheal tubes, 295f Specific dynamic action, 182 Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for, 250 side effects of, 305 inactivation of, 305 side effects of, 305 inactivation of, 305 side effects of, 305 tracheostomy tube and, 435–440 Suction catheters flexible, 222f Therapeutic PEEP, 251 Therapeutic	concerns with, 439	Substrate utilization pattern, 182-183,	-
Specific dynamic action, 182 Speech  loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, Spontaneous CPAP, circuitry for, 250  Speech side effects of, 305 Usction of, 305 Suction catheters flexible, 222f reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, Spentaneous CPAP, circuitry for, 250  Specific dynamic action, 305 inactivation of, 305 side effects of, 305 Thermal flow meters, 184–185 Thermodilution catheters, 197 Thoracic pressure-volume relations, patterns of alteration in, 354t Thoracic prespure-volume longs, baced on endotracheal tube size, 222b  Suctioning assessment after, 225–226, 225b duration of, 222, 223  Sudden distress, identification of patient in, 348–349, 348b causes of, 348b  Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b suctional catheters, 197 Thoracic pump mechanism, 310 Thorax c	Specialized continuous suction endo-		=
Specch side effects of, 305 loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250 side effects of, 305 usage of, 305 usage of, 305 Suction catheters flexible, 222f reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 349b ventilation maintenance in, 409–410 Spontaneous Breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  Inactivation of, 305 usage of, 305  Suction catheters flexible, 222f reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b causes of, 348b causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous catheter placement, 135	tracheal tubes, 295f	Succinylcholine, 305	• •
Speech loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for, 250 suction catheters flexible, 222f reuse of, procedure in, 441b suction catheters fhermal flow meters, 184–185 Thermaclilution catheters, 197 Thoracic pressure-volume relations, patterns of alteration in, 354t Thoracic pump mechanism, 310 Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	Specific dynamic action, 182	inactivation of, 305	
loss of, 436 tracheostomy tube and, 435–440 Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for, 250 Suction catheters flexible, 222f reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous Spontaneous CPAP circuitry for, 250  Spontaneous CPAP circuitry for, 250  Suction catheters Thermodilution catheters, 197 Thoracic pressure-volume relations, patterns of alteration in, 354t Thoracic pump mechanism, 310 Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	Speech	side effects of, 305	
Spontaneous breathing, 2, 73 airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250 airway pressure during, 495 flexible, 222f reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous  Catheter placement, 135  Thoracic pressure-volume relations, patterns of alteration in, 354t Thoracic pump mechanism, 310 Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Tridal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	loss of, 436	usage of, 305	
airway pressure during, 495 device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  airway pressure during, 495 reuse of, procedure in, 441b size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous catheter placement, 135	tracheostomy tube and, 435-440	Suction catheters	
device for delivering heliox in, 505–506, 505b prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous  catheter placement, 135  Thoracic pump mechanism, 310 Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	Spontaneous breathing, 2, 73	flexible, 222f	-
tube size, 222b  prolonged, 334 thoracic pump mechanism during, 310 Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  size (estimation), based on endotracheal tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous Spontaneous CPAP circuitry for 250  Thorax computed tomographs of, 265f positive-pressure ventilation and, 310, 310b Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	airway pressure during, 495	reuse of, procedure in, 441b	-
tube size, 222b  prolonged, 334 thoracic pump mechanism during, 310  Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  tube size, 222b Suctioning assessment after, 225–226, 225b duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b pressure-volume loops and, 151, 154f Superior vena cava, indwelling venous  catheter placement, 135  computed tomographs of, 265f positive-pressure ventilation and, 310, 310b  Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation and, 310, 310b	device for delivering heliox in, 505-506,	size (estimation), based on endotracheal	
thoracic pump mechanism during, 310  Spontaneous breathing trial (SBT), 73, 400, 401b     assessment during, 403, 403b     failure, 399b     recommendation in, 405, 405b     problems during, clinical signs and     symptoms indicating, 403b     ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65     pressure-volume loops and, 151,     154f  Spontaneous CPAP circuitry for, 250  Sudctioning     assessment after, 225–226, 225b     duration of, 222–223     hazards and complications of, 223,     223b  Sudden distress, identification of patient     in, 348–349, 348b     causes of, 348b  Sudden respiratory distress     causes of, 349b     clinical scenario, 350b     management of, 349b  Superior vena cava, indwelling venous  CPAP circuitry for, 250  Stationing     assessment after, 225–226, 225b     duration of, 222, 223b  Thrombolytic therapy, 351  Tidal flow-volume loops, based on mechanical breaths, 232f  Tidal volume (V <sub>T</sub> ), 465     case study on, 90b     changes, examples of, 141t     delivery     capability of, 111     in pressure ventilation and, 310, 310b	505b	tube size, 222b	
ssessment after, 225–226, 225b  Spontaneous breathing trial (SBT), 73, 400, 401b	prolonged, 334	Suctioning	
Spontaneous breathing trial (SBT), 73, 400, 401b assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Spontaneous CPAP circuitry for 250  duration of, 222–223 hazards and complications of, 223, 223b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous  catheter placement, 135  Threshold resistors, 250, 251b Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	thoracic pump mechanism during, 310	assessment after, 225-226, 225b	
assessment during, 403, 403b failure, 399b recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f  Spontaneous CPAP circuitry for 250  assessment during, 403, 403b Sudden distress, identification of patient in, 348–349, 348b causes of, 348b Sudden respiratory distress causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous  catheter placement, 135  Thrombolytic therapy, 351 Tidal flow-volume loops, based on mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	Spontaneous breathing trial (SBT), 73, 400,	duration of, 222-223	
failure, 399b  failure, 399b  recommendation in, 405, 405b  problems during, clinical signs and symptoms indicating, 403b  ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65  pressure-volume loops and, 151, 154f  Spontaneous CPAP circuitry for 250  Sudden distress, identification of patient in, 348–349, 348b  causes of, 348b  Sudden respiratory distress  causes of, 349b  clinical scenario, 350b  management of, 349b  Superior vena cava, indwelling venous  catheter placement, 135  Tidal flow-volume loops, based on mechanical breaths, 232f  Tidal volume (V <sub>T</sub> ), 465  case study on, 90b  changes, examples of, 141t  delivery  capability of, 111  in pressure ventilation, 97–98  display, 129	401b	hazards and complications of, 223,	
recommendation in, 405, 405b problems during, clinical signs and symptoms indicating, 403b ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Superior vena cava, indwelling venous Spontaneous CPAP circuitry for 250 Sudden distress, identification of patient mechanical breaths, 232f Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	assessment during, 403, 403b	223b	
problems during, clinical signs and symptoms indicating, 403b Sudden respiratory distress ventilation maintenance in, 409–410 Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f Superior vena cava, indwelling venous catheter placement, 135  Tidal volume (V <sub>T</sub> ), 465 case study on, 90b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	failure, 399b	Sudden distress, identification of patient	
symptoms indicating, 403b ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65 pressure-volume loops and, 151, 154f  Superior vena cava, indwelling venous  Spontaneous CPAP circuitry for 250  Superior vena cava, indwelling venous  Causes of, 348b  causes of, 348b claircas  causes of, 349b clinical scenario, 350b management of, 349b Superior vena cava, indwelling venous  Catheter placement 135  causes of, 348b changes, examples of, 141t delivery capability of, 111 in pressure ventilation, 97–98 display, 129	recommendation in, 405, 405b	in, 348-349, 348b	
symptoms indicating, 403b  ventilation maintenance in, 409–410  Spontaneous breaths, 43, 65  pressure-volume loops and, 151,  154f  Superior vena cava, indwelling venous  Spontaneous CPAP circuitry for 250  causes of, 349b  clinical scenario, 350b  management of, 349b  Superior vena cava, indwelling venous  catheter placement 135  changes, examples of, 141t  delivery  capability of, 111  in pressure ventilation, 97–98  display, 129	problems during, clinical signs and	causes of, 348b	
Spontaneous breaths, 43, 65 clinical scenario, 350b pressure-volume loops and, 151, management of, 349b capability of, 111 in pressure ventilation, 97–98 Superior vena cava, indwelling venous  Spontaneous CPAP circuitry for 250 catheter placement, 135		Sudden respiratory distress	•
pressure-volume loops and, 151, management of, 349b  154f Superior vena cava, indwelling venous  Spontaneous CPAP circuitry for 250 catheter placement 135  capability of, 111 in pressure ventilation, 97–98 display, 129	ventilation maintenance in, 409-410	causes of, 349b	
pressure-volume loops and, 151, management of, 349b in pressure ventilation, 97–98  154f Superior vena cava, indwelling venous  Spontaneous CPAP circuitry for 250 catheter placement 135	Spontaneous breaths, 43, 65	clinical scenario, 350b	•
Spontaneous CPAP circuitry for 250 catheter placement 135 display, 129	pressure-volume loops and, 151,	management of, 349b	
Spontaneous CPAP circuitry for 250 catheter placement 135			-
now derivery, dependence on, 175	Spontaneous CPAP, circuitry for, 250	catheter placement, 135	flow delivery, dependence on, 495

Tidal volume (V <sub>T</sub> ) (Continued)	Tracheostomy (Continued)	Upper airway (Continued)
flow, total cycle time, and inspiratory-to	role of, in weaning, 399b, 410-411	topical anesthesia to, 235
expiratory ratio, relationship, 91-92,	speaking valves, 437–439	Upper inflection point, 267
91b	Tracheostomy tubes, 250, 426, 435-440	User interface (control panel), 18, 20-21,
increasing (clinical scenario), 215b	care of, 294–295	22f
measurement, respirometer technique for,	child with, 438b	
129f, 129b	complications, 341b	V
during PC-CMV, 97b	connector for, 437-438	
positive end-expiratory pressure, effect of,	cuffs, management of, 136-140	VAIs. See Ventilator-assisted individuals
463f	early placement of, 435-436	VALI. See Ventilator-associated lung injury
rate and, 88-91	selection and benefits of, 435-436	VAP. See Ventilator-associated pneumonia
settings, 90b	speaking, 436-437	VAPS. See Volume-assured pressure
in ARDS, 267–268	during ventilation, speaking with, 436	support
usage, 109b	Train-of-four (TOF), assessment of, 305,	Variable capacitance, 183
Time constants, 8-9, 8b	305b	Variable orifice pneumotachometers, 184—185, 184f
calculation of, 8b, 463b	Transairway pressure (P <sub>TA</sub> ), 3, 131, 151	Variable pressure support/control, 397
concept of, 465	airway resistance measurement and, 7	Vascular endothelial injury, 325–326
passive exhalation and inhalation and, 9f	Transcutaneous electrodes, 179f	Vascular reflexes, blocked, 311
percentage change in pressure in,	Transcutaneous monitoring, 178-180	Vascular resistance, 206
464-465, 465f	clinical practice guideline for, 178b	Vascular tone, changes in, 200
Time-controlled breathing, 32	pulse oximeters and, 466	VC-CMV. See Volume-controlled con-
Time controller, 31	technical considerations in, 179-180	tinuous mandatory ventilation
Time-cycled breath, pressure-limited, 36	Transcutaneous partial pressure of O <sub>2</sub>	VC-IMV. See Volume-controlled inter-
Time-cycled inspiration, 75b	$(P_{tc}O_2)$ , 178–179, 179f	mittent mandatory ventilation
Time-cycled, pressure-limited, intermittent	Transcutaneous PCO <sub>2</sub> , 179, 179f	VDR-4, 476
mandatory ventilation (TCPL/IMV),	Transcutaneous PO <sub>2</sub> , 178-179, 179f	Vecuronium, 306
458-459	Transdiaphragmatic pressure, 187, 189f	effectiveness of, data on, 306
Time-cycled ventilator	Transport ventilators, 427b	Vecuronium bromide (Norcuron), 306
effects of changing flow pattern in, 94-95	examples of, 427-428	Venous return
examples of, 39, 94t	Transpulmonary pressure (P <sub>L</sub> or P <sub>TP</sub> ),	changes in, 95–96
inspiratory flow in, 92b	3-4, 266b	reduction, positive pressure ventilation
Time, flow, pressure, volume	breathing and, 30-31	and, 128b
(relationship), 148, 148b	changes in, 5t	Ventilated patients
Time-triggered, pressure-limited, time-	chest-wall and, 323b	administering aerosols to, 226, 227f, 227b
cycled ventilation (TPTV), 459f	components of, 4	management techniques and therapies in,
Time triggering, 34	Transrespiratory pressure (P <sub>TR</sub> ), 4	235
Tissues, oxygen delivery to, basics of,	Transthoracic pressure (P <sub>W</sub> ), 3	$P_aO_2$ , $S_pO_2$ , $F_IO_2$ evaluation in, 246–247
246-248	Trigger asynchrony, 157, 157f, 335-336,	severe respiratory distress, evaluation of
Titrating ventilator, methods of, 393–395	335f-336f	case study on, 351b
Total cycle time (TCT), 34	Triggering	transport of, support equipment and
calculation of, 91-92	case study on, 106b	monitoring equipment for, 238b
tidal volume and, relationship, 91–92	mechanism (trigger variable), 34	Ventilation, 2
Total face mask, 379-382, 381f	Trigger sensitivity, 352	abnormalities, correction of, 214
Total oxygen consumption (VO <sub>2</sub> ), 86	Trigger variable, 34–35, 34b	adequacy of, indicator of, 52b
Total resistance, 141	Tris-hydroxymethyl-aminomethane	adjusting, 496–497
Total respiratory cycle, pressure readings	(THAM), 220	backup mode of, 356
in, 313f	Tubing compliance, 88–90	basic model of, 30–31
Total shunt fraction, 206	calculating volume lost to, 90b	changes, methods of, based on PaCO2 and
T-piece weaning, 395	correction of, 130	pH, 214–221
Trachea, damage to, 341b	Tubing compressibility, 38	dead space, 176b
Tracheal buttons, 435-440, 440f	Turbine flow meters, 185	depression of, 333
decannulation and, 439-440		determination of, 449, 496
Tracheal dilation, 138f	U	failure of, 53
Tracheal injury, from long-term	Ultrasonic flow transducers, 184f	flow-cycled, 39, 39f
ventilation, 430b	Ultrasonic nebulizers, 228	gas flow during, 2
Tracheal intubation, capnography in, 175b	Unilateral lung disease, patient position in,	intubation without, 56
Tracheal necrosis, 137–138	278-279	maintenance of, 502
Tracheal pressure curve, using inspiratory	Unintubated patient, resistance values for,	manual, 110
pressure support, 396f	7b	mode of, 64-67, 128
Tracheoesophageal fistula, 451	Unseated expiratory valve, 361-362	determination of, 150, 151b, 152f-153f
Tracheomalacia, 456	Upper airway	selection of, 30
Tracheostomy	infections, sputum and, 235	neural control of, 510
complications associated with, 341b	pressure, 3	in neuromuscular disorders, case study,
consideration for, 410-411	graph of, 12f	50b

Ventilation (Continued)	Ventilator CPAP, 452-453	Ventilators (Continued)
to nondependent lung, 327	Ventilator-dependent patients	modes, 31, 62-84
parameters, case study on, 142b	early tracheostomy tube placement in,	spontaneous, 73–75
perfusion without, 205, 248b	advantages of, 435b	worksheet for reviewing, 81f
pressure-cycled, 39-40	at home site, respiratory care plan	needs, 110
pressure gradients during, 2	equipment checklist for, 427b	noninvasive and invasive positive pressure
prolongation of, in long-term care	sites for, 420	ventilation, 63-64
facilities, 399b, 412	Ventilator graphics, 147-165	operation, verification of, 125b
review of neural control of, 510	problem solving using, case study on,	parameters, PEEP and, 255-256
solving problems in, 347	358b	patient performance with, 401-402
strategy, improving, 496	for pulmonary mechanics monitoring,	performance, evaluation of, 111
time-cycled, 38–39	154-156, 154f-155f, 155b, 156f	pneumatically powered, 18-19, 19b
tracheostomy tubes during, speaking with,	scalars, 148-150, 149f	pneumatic circuit, 21-23
436	troubleshooting for, 347b	power source of, 18-19
types of, 10	Ventilator-induced diaphragm dysfunction,	power transmission and, 23-26
volume-cycled, 38	512	problems in, 351–353
Ventilation-to-lung periphery, 327	Ventilator-induced lung injury (VILI), ven-	evaluation of, 361b
Ventilation-to-perfusion (V/Q), 95	tilator-associated lung injury versus,	identification of, use of graphics in,
mismatching in, 47, 253-254	321, 321b	356-360, 358b
relationships, 172f	Ventilator-induced respiratory alkalosis,	procedures, 252t
Ventilator alarms, 107, 108b	408t	PRVC names on, 100t
inoperative, technical error message and,	Ventilator-induced respiratory muscle	rate, display, 129
356	weakness, 326–327	requirement, clinical scenario, 95b
situations, action during, 109	Ventilator management protocol (VMP),	selection of, 110–111, 426–428
Ventilator-assisted individuals (VAIs), 419	411f	case study on, 19b
cuff deflation of, 436	Ventilator-related problems, 351–353	sensitivity setting in, 104–107, 104b, 105i
discharge of, preparation for, 422–424	Ventilators, 17–28, 62–84	106b, 129
psychological problems in, 430	additional modes of ventilation in, 76–80	setup
Ventilator-associated lung injury (VALI),	artificial intelligence system for, 395	final considerations in, 103–123
ventilator-induced lung injury versus,	asynchrony, resolution for, 353b	parameters, 103–104
321, 321b	bilevel positive airway pressure in, 75–76,	single-circuit, 21, 22f
Ventilator-associated pneumonia (VAP),	76b	synchrony, using waveform, 513–514
286—298, 287b	breath delivery in, 64–65	technical error message and, 356
	·	•
algorithm of, 291, 292f	changes in, case study on, 329b	tidal volume, display, 129
bacteriologic (quantitative) diagnosis of,	classification, historical perspective on, 17–18	troubleshooting, 357b
291		types of, 375–378
causes and risk factors of, 287–289,	components of, 18b	unexpected responses to, 361–364
287b—288b	compressors (blowers), 23–24	user interface (control panel), 18, 20–21,
CDC surveillance paradigm for, 289, 290t	control systems and circuits of, 19–23	22f
clinical diagnosis of, 289–291	conversion system and, 23–26	volume displacement designs, 24–26
diagnosis of, 289–291	cost of purchasing of, 111	volume flow-control valves, 26
clinical criteria used in, 290t	dependence, pathology of, 398, 399b	Ventilator settings, recommending changes
endotracheal tube and, 294	discontinuation of, closed-loop control	in, 468b
epidemiology of, 287–289	modes for, 395–398	Ventilatory assist, neurally adjusted,
handwashing and, 293–294, 293b	double-circuit, 21–23, 23f	514-516
incidence of, 287	drive mechanisms in, 23	Ventilatory management, and discontinua-
management of	electrically powered, 18b	tion, components of, 392b
antibiotic regimens used for, 292f	equipment setup, final considerations in,	Ventilatory mechanics
noninvasive ventilation and, 294	110	adult and critical range values of, 51t
nonpharmacological interventions for,	flow sheet, 125, 126f	bedside measurement of, 51–53
293-295	comment section of, 144	Ventilatory muscle function, 400b
pathogenesis of, 289	fluid logic (fluidic) pneumatic	Ventilatory support
patient case of, 291b	mechanisms, components of, 20f	discontinuation of, 373
pharmacological interventions for, 295-296	full and partial ventilatory support in, 64	establishment of, 374
positioning and enteral feeding and, 294	function of, 494b	inadequate, 352
prevention of, strategies for, 291–296, 293b	with heliox, 508b	indications for
treatment of, 291, 293b	worksheet for reviewing, 81f	in neonates, 457–458
Ventilator circuits	input power of, 18–19	in pediatric patients, 458
disinfection of, 440-441	inspiratory waveform maintenance, 32f	methods of titrating, 393-395
leaks, checking for, 133-134, 133f, 133b	internal function of, 18	newborn and pediatric, 450
management strategies for, 295, 295b	mechanical and operational hazards of,	postmyocardial infarction, 95b
Ventilator control	339, 339b—340b	withholding and withdrawing, ethical
panel, user interface, 20-21, 22f	methods of, comparison of, 395	dilemma on, 412
systems and circuits, 19-23	minute ventilation, display, 129	Ventricular rate, decreased, 204

Vest Airway Clearance System, 233f	Volume displacement designs (Continued)	Weaning (Continued)
Vibrating mesh nebulizers, 228 Viscous resistance, 7	example of, 25b—26b	exercise and, 408–409
Visual alarms, 107	linear drive piston, 25b—26b rotary drive piston, 25b—26b	goals for, 412 hyperventilation and, 329
activation of, 133	spring-loaded bellows, 25b—26b	index, requirements of, 401b
Visual analog scale, 238f	Volume flow-control valves, 26	in long-term ventilation units, 399b
Vital capacity (VC), 50, 52	Volume limiting, 37	metabolic factors in, 408
bedside measurement of, 53b	Volume support	nonrespiratory factors in, 407t
Vital signs, 134–135	initial settings of, 100	nutritional status and, 408–409
assessment of, 112b–113b	names for, 100t	parameters of, 401t
Voice tracheostomy tube (VTT), 436–437	Servo-i, 112	patient's ability for, 403
Volume	test breath, 78f	pharmacologic agents on, effect of, 408
control mode, 467	time-cycled and pressure-cycled	physiological parameters for, 401t
pressure-regulated, 469, 469f	inspiration with, 75b	protocols for, 399b, 410, 410b
delivery	Volume support ventilation (VSV), 77, 78f,	efficiency and effectiveness of, 410b
delayed in, 463f	472	example of, 411f
graphs, 94f	Volume-targeted continuous mandatory	psychological factors in, 409
device (bellows), usage, 6f	ventilation, 70	disease-related issues and, 409
evaluation of, case study on, 355b	Volume-targeted pressure support ven-	manifestations of, 409
expiratory portion of, 347f	tilation, 397	psychological fears on, 409
flow, pressure, time relationship, 148,	Volume-targeted ventilation	readiness assessment for, evaluation
148b	advantage of, 96	criteria for, 403
guarantee, 469-472, 470f	V <sub>T</sub> and, 467	sedation strategies and protocols for, 410
loss, calculation of, to tubing compliance,	Volume-time curve, 347f	techniques, 392–393
90b	below baseline, expiratory portion of, 360	term, use of, 392, 392b
pressure-regulated, 469, 469f	problem, 362f	titrating ventilator support during,
scalars, 152f-154f	Volume-time waveforms, 36, 37f, 133f	393-395
targeting, pressure ventilation modes with,	Volumetric capnometry, 175-177, 176f	T-piece, 395
99	Volume triggering, 34	tracheostomy in, role of, 399b
Volume-assured pressure support (VAPS),	Volume ventilation, 507	work of breathing during, 333-334
76, 112	initial ventilator settings for, 86b	Weaning failure
Volume-controlled breathing, 32	inspiratory pause during, 95-96, 95b	clinical scenario on, 410b
Volume-controlled continuous mandatory	Volume waveforms, flow pressure and,	criteria for, 406b
ventilation (VC-CMV), 70	471f	factors in, 405
advantages, risks, and advantages of, 74t	Volutrauma, barotrauma and, 323-324	Webb and Tierney study, 326
goal of, 86	Vortex ultrasonic flow meters, 184, 184f	Wheatstone bridge, 195-196, 195f
graphs of, 70f	Vyaire 3100B	Wiggers diagram, 193
inspiratory pause, setting of, 133f	control panel of, 499f	illustration of, 194f
scalars, 148	schematic of, 498f	WOB. See Work of breathing
volume-time waveform during, 133f		Women, ideal body weight for, calculating,
Volume-controlled inspiration, 33b	w	88b
Volume-controlled intermittent mandatory	Wall attachment phenomenon, 20f	Work of breathing (WOB), 48b, 186, 402,
ventilation (VC-IMV)	Water traps, emptying, 107	402b
advantages, risks, and advantages of, 74t	Waveforms (curves), 147–148, 148b	chest trauma and, 51
scalars, 149-150, 150f, 153f-154f	abnormal, ventilator response to, 357b	during continuous positive airway
Volume-controlled ventilation, 31b, 33f,	ringing, 359–360, 363f	pressure, 188f
69b, 86b	Weaning, 482–483	defined, 186
airway pressure waveform during, 130f	acid-base factors in, 408	graphic representation of, 186-187,
flow constancy and, 336	anesthesia strategies and protocols for,	187f—188f
initial settings during, 86-95	410	increased, 50-51, 333-339
peak inspiratory pressure (PIP) and	APRV settings, example of, 497t	measurement of, 334
plateau pressure (P <sub>plat</sub> ), evaluation of,	attempt	physical signs and measurements of, 402b
355b	evaluation of, case study on, 394b	reduction of, steps for, 334–339
pressure-controlled ventilation versus, 150,	failed, case study on, 408b	ventilator, performed by, 334b
150b	cardiac factors in, 406	during weaning, 333-334, 334b
Volume-cycled breath, inspiratory phase	clinical criteria for, evaluation of,	
of, 38	398-405	Υ
Volume-cycled ventilation, 38	clinical scenario on, 409b	Y-connector, 90–91, 437–438
Volume-cycled ventilators, 38	complication of, nonrespiratory factors in,	, , , , , , , , , , , , , , , , , , ,
effects of changing flow pattern in, 94–95	405-410	7
example of, 94t	criteria for, 400-401	<b>Z</b>
flow and volume delivery during, 94f	difficulty in, case study on, 422b	ZEEP. See Zero end-expiratory pressure
flow patterns in, 94f	evidence-based, 398	Zero end-expiratory pressure (ZEEP), 40
Volume displacement designs, 24-26		